<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32308619</article-id>
<article-id pub-id-type="pmc">7145900</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2020.00278</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Unraveling Host-Gut Microbiota Dialogue and Its Impact on Cholesterol Levels</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Villette</surname>
<given-names>Remy</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/876915" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>KC</surname>
<given-names>Pukar</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/864751" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Beliard</surname>
<given-names>Sophie</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/937420" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Salas Tapia</surname>
<given-names>Maria Fernanda</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/918449" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rainteau</surname>
<given-names>Dominique</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/642707" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guerin</surname>
<given-names>Maryse</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/764881" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lesnik</surname>
<given-names>Philippe</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/715458" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>INSERM, UMRS U1166, “Integrative Biology of Atherosclerosis” and Sorbonne Université</institution>, <addr-line> Paris</addr-line>, <country>France</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Aix-Marseille Université, INSERM U1263, INRA, C2VN</institution>, <addr-line> Marseille</addr-line>, <country>France</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>APHM, La Conception Hospital</institution>, <addr-line>Marseille</addr-line>, <country>France</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, AP-HP, Hôpital Saint Antoine, Département de Métabolomique Clinique</institution>, <addr-line>Paris</addr-line>, <country>France</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Amedeo Amedei, University of Florence, Italy</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Ian James Martins, University of Western Australia, Australia; Jonel Trebicka, Goethe University Frankfurt, Germany</p>
</fn>
<corresp id="fn001">*Correspondence: Philippe Lesnik, <email xlink:href="mailto:philippe.lesnik@inserm.fr" xlink:type="simple">philippe.lesnik@inserm.fr</email>
</corresp>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>03</day>
<month>4</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>11</volume>
<elocation-id>278</elocation-id>
<history>
<date date-type="received">
<day>06</day>
<month>12</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>2</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2020 Villette, KC, Beliard, Salas Tapia, Rainteau, Guerin and Lesnik</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Villette, KC, Beliard, Salas Tapia, Rainteau, Guerin and Lesnik</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Disruption in cholesterol metabolism, particularly hypercholesterolemia, is a significant cause of atherosclerotic cardiovascular disease. Large interindividual variations in plasma cholesterol levels are traditionally related to genetic factors, and the remaining portion of their variance is accredited to environmental factors. In recent years, the essential role played by intestinal microbiota in human health and diseases has emerged. The gut microbiota is currently viewed as a fundamental regulator of host metabolism and of innate and adaptive immunity. Its bacterial composition but also the synthesis of multiple molecules resulting from bacterial metabolism vary according to diet, antibiotics, drugs used, and exposure to pollutants and infectious agents. Microbiota modifications induced by recent changes in the human environment thus seem to be a major factor in the current epidemic of metabolic/inflammatory diseases (diabetes mellitus, liver diseases, inflammatory bowel disease, obesity, and dyslipidemia). Epidemiological and preclinical studies report associations between bacterial communities and cholesterolemia. However, such an association remains poorly investigated and characterized. The objectives of this review are to present the current knowledge on and potential mechanisms underlying the host-microbiota dialogue for a better understanding of the contribution of microbial communities to the regulation of cholesterol homeostasis.</p>
</abstract>
<kwd-group>
<kwd>gut microbiota</kwd>
<kwd>microbiome</kwd>
<kwd>gut metabolites</kwd>
<kwd>cholesterol</kwd>
<kwd>LDL-cholesterol</kwd>
<kwd>cholesterolemia</kwd>
<kwd>dyslipidemia and cardiovascular disease</kwd>
</kwd-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="2"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="191"></ref-count>
<page-count count="15"></page-count>
<word-count count="6998"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Atherosclerosis is the underlying cause of the majority of cardiovascular disease (CVD) events, the complications of which can be fatal (myocardial infarction, sudden death, and ischemic cerebral accidents). According to WHO projections, exposure to multiple genetic and environmental risk factors and the growing number of dysmetabolic conditions (metabolic syndrome, type 2 diabetes mellitus, obesity, non-alcoholic fatty liver diseases) will contribute to making atherosclerotic cardiovascular disease (ACVD) a leading cause of death in the world by 2030 (<xref ref-type="bibr" rid="B79">Kaptoge et al., 2019</xref>). Among the etiological factors of this multifactorial pathology, circulating levels of total cholesterol (TC) or LDL-Cholesterol (LDL-C) represent major risk factors for ACVD. Consistent evidence from numerous epidemiological, clinical, and genetic studies unequivocally establishes a causal role of LDL-C in ACVD (<xref ref-type="bibr" rid="B46">Ference et al., 2017</xref>). A major instigating event is the recognition of oxidized-LDL-C by immune cells due to molecular mimicry with foreign antigens, thus promoting chronic inflammatory and self-perpetuating responses (<xref ref-type="bibr" rid="B176">Wolf and Ley, 2019</xref>).</p>
<p>Genetics plays an important role in regulating the levels of TC and associated lipoproteins (<xref ref-type="bibr" rid="B160">van Dongen et al., 2013</xref>; <xref ref-type="bibr" rid="B66">Hoffmann et al., 2018</xref>), yet genetic variation may account for 20% of plasma cholesterol levels (<xref ref-type="bibr" rid="B150">Surakka et al., 2015</xref>; <xref ref-type="bibr" rid="B66">Hoffmann et al., 2018</xref>). Environmental factors such as the amount and composition of the diet (<xref ref-type="bibr" rid="B109">Mente et al., 2017</xref>) as well as dietary cholesterol intake (<xref ref-type="bibr" rid="B58">Griffin and Lichtenstein, 2013</xref>) are well-established contributors; however, the individual-level contribution of intestinal microbiota to cholesterol homeostasis and the relevant pathways through which microbiota may exert their actions need to be documented and characterized. The gut microbiota functions as an endocrine system, which communicates with distal organs through metabolic pathways (<xref ref-type="bibr" rid="B23">Cani and Knauf, 2016</xref>). Additionally, modifications in the gut microbial ecosystem induced by external factors may cause radical changes in the symbiotic relationship between the microbiota and the host, and thus contribute to the low-grade inflammation that is constitutive of metabolic diseases (<xref ref-type="bibr" rid="B22">Cani et al., 2007</xref>; <xref ref-type="bibr" rid="B45">Fändriks, 2017</xref>). As a consequence, these modifications may account for a substantial proportion of the variation of plasma lipids, including cholesterol levels (<xref ref-type="bibr" rid="B52">Fu et al., 2015</xref>). In this context, the objectives of this review are to explore pre-clinical and clinical evidence and mechanisms linking gut microbiota and host-cholesterol metabolism in conditions of normal or altered homeostasis.</p>
</sec>
<sec id="s2">
<title>Classical Risk Factors Associated With Cholesterolemia</title>
<p>Genome-wide association studies (GWAS) have identified multiple human genetic variants contributing to plasma LDL-C and TC concentrations (<xref ref-type="bibr" rid="B172">Willer et al., 2013</xref>; <xref ref-type="bibr" rid="B150">Surakka et al., 2015</xref>; <xref ref-type="bibr" rid="B101">Liu et al., 2017</xref>; <xref ref-type="bibr" rid="B66">Hoffmann et al., 2018</xref>). These latter studies identified 289 and 189 independent variants significantly associated with circulating levels of TC and LDL-C, respectively (<xref ref-type="bibr" rid="B172">Willer et al., 2013</xref>; <xref ref-type="bibr" rid="B101">Liu et al., 2017</xref>). These genetic polymorphisms collectively account for the phenotypic variance of nearly 20% of TC and LDL-C (<xref ref-type="bibr" rid="B150">Surakka et al., 2015</xref>; <xref ref-type="bibr" rid="B66">Hoffmann et al., 2018</xref>). Among them, only 1.7 to 2.5% of subjects with elevated LDL-C levels were carrying the known genetic variants identified from familial hypercholesterolemia (LDLR, APOB, and PCSK9) (<xref ref-type="bibr" rid="B1">Abul-Husn et al., 2016</xref>; <xref ref-type="bibr" rid="B82">Khera et al., 2016</xref>). The results of both twin and family studies estimated a heritability of 46-57% for TC and LDL-C (<xref ref-type="bibr" rid="B182">Yu et al., 2005</xref>; <xref ref-type="bibr" rid="B57">Goode et al., 2007</xref>; <xref ref-type="bibr" rid="B160">van Dongen et al., 2013</xref>). In this respect, we can estimate that environmental/lifestyle factors may account for not less than 50% and up to 80% of the complementary fluctuations of TC and LDL-C. Moreover, development of atherosclerosis and regulation of plasma TC and LDL-C levels are also closely linked to consumption of dietary fatty acids, dietary fibers, carbohydrates, and alcohol, as well as to obesity, tobacco use, and level of physical activity (<xref ref-type="bibr" rid="B183">Yusuf et al., 2004</xref>); most of these CV risk factors are correlated with significant changes in the gut microbial ecosystem (<xref ref-type="bibr" rid="B25">Cerdá et al., 2016</xref>; <xref ref-type="bibr" rid="B29">Costantini et al., 2017</xref>; <xref ref-type="bibr" rid="B134">Savin et al., 2018</xref>; <xref ref-type="bibr" rid="B108">Medina et al., 2019</xref>; <xref ref-type="bibr" rid="B133">Sarin et al., 2019</xref>). Among the best known, saturated-fatty acids, trans-fatty acids, and fibers are the nutritional factors that have the most significant impact on LDL-C (<xref ref-type="bibr" rid="B48">Fernandez, 2001</xref>; <xref ref-type="bibr" rid="B125">Riccioni et al., 2012</xref>).</p>
<p>Reduction in body weight in severely obese subjects has a modest influence on TC and LDL-C, with each kilogram lost associated with a decrease of ∼0.8 mg/dL in LDL-C. When weight reduction is even higher (e.g., bariatric surgery), the cholesterol-lowering effect is even more pronounced (<xref ref-type="bibr" rid="B8">Benetti et al., 2013</xref>). LDL-C can be reduced by regular physical activity (<xref ref-type="bibr" rid="B94">Leon and Sanchez, 2001</xref>), as suggested by new genetic variants interacting with physical activity and associated with cholesterol levels (<xref ref-type="bibr" rid="B84">Kilpeläinen et al., 2019</xref>). Additionally, other common causes of elevated LDL-C such as biliary obstruction, nephrotic syndrome, hypothyroidism, and pregnancy (<xref ref-type="bibr" rid="B146">Stone et al., 2014</xref>) have been connected to adverse effects on the gut microbiota composition (<xref ref-type="bibr" rid="B44">Ejtahed et al., 1969</xref>; <xref ref-type="bibr" rid="B157">Tsuji et al., 2018</xref>; <xref ref-type="bibr" rid="B102">Lv et al., 2019</xref>; <xref ref-type="bibr" rid="B165">Vieira-Silva et al., 2019</xref>).</p>
</sec>
<sec id="s3">
<title>The New Player: Commensal Gut Microbiota</title>
<p>In the last decade, research developments have positioned the commensal gut microbiota at the interface between living organisms and the environment and demonstrated its considerable influence on optimum metabolic functioning (<xref ref-type="bibr" rid="B138">Sekirov et al., 2010</xref>). One of the contributions of gut bacteria to host biology is the circulating pool of bacteria-derived metabolites (<xref ref-type="bibr" rid="B115">Nicholson et al., 2012</xref>), which can reach or exceed concentrations achieved by a typical drug dose (μM to mM). In many cases, these co-metabolites signal through specific receptors and impact multiple metabolic pathways and host biology. Nearly half of the circulating metabolites are believed to come from bacterial metabolism (<xref ref-type="bibr" rid="B170">Wikoff et al., 2009</xref>; <xref ref-type="bibr" rid="B144">Sridharan et al., 2014</xref>). In the symbiotic relationships established between resident microorganisms and the host, bacteria benefit from a stable environment (nutrients, temperature, pH, osmolarity, oxygen pressure), and the biological functions of the microbiota are increasingly seen as essential to health: maturation of the immune system, metabolic and nutritional functions, and protection against pathogens. A growing number of pathologies are associated with combined quantitative and qualitative dysbiotic changes in the intestinal microbiota composition and function: diabetes, obesity, cancer, inflammatory bowel disease, autoimmune and allergic diseases, autism spectrum disorders, anxiety, and depression (<xref ref-type="bibr" rid="B103">Lynch and Pedersen, 2016</xref>). The microbiota thus appears to be a critical player at the crossroads of physiology and multiple pathologies. It is also emerging as a powerful transmission channel of environmental changes linked to diet and exposure to drugs, antibiotics, pollutants, and infectious agents. Microbiota modifications induced by recent changes in the human environment thus seem to be a determining factor in the current epidemic of chronic metabolic and inflammatory diseases.</p>
<p>More than 65 million years of mammalian-microbe co-evolution has led to an interdependence. The diversity of bacterial genes allows a wide variety of metabolic activities, such as energy extraction (5–10% of the daily energy requirements of the host) by digesting macromolecular complexes (polysaccharides, glycosaminoglycans, glycoproteins) that are not easily digestible by humans. Bacterial genes also allow the synthesis of vitamins (<xref ref-type="bibr" rid="B181">Yoshii et al., 2019</xref>), neurotransmitters (<xref ref-type="bibr" rid="B118">Onaolapo et al., 2020</xref>), and metabolites derived from tryptophan (<xref ref-type="bibr" rid="B3">Agus et al., 2018</xref>); they can also provide substrates that can feed critical metabolic pathways of the host (short-chain fatty acids) (<xref ref-type="bibr" rid="B149">Sun et al., 2017</xref>); they metabolize steroids such as cholesterol (<xref ref-type="bibr" rid="B4">Allayee and Hazen, 2015</xref>) or its derivatives, for instance, bile acids (<xref ref-type="bibr" rid="B126">Ridlon et al., 2014</xref>) and can thus influence the metabolism of lipids and cholesterol of the host. They can also contribute to or suppress the detoxification of xenobiotics and the biological activities of drugs (<xref ref-type="bibr" rid="B88">Koppel et al., 2017</xref>). In this ecosystem, eukaryotic and prokaryotic genes will constitute a reservoir of metabolic response that can be mobilized as a function of nutritional and xenobiotic intakes (<xref ref-type="bibr" rid="B51">Foster et al., 2017</xref>).</p>
<p>However, the complexity of intestinal microbial communities and their dialogue with the host’s metabolic pathways make functional connections complicated to disentangle in these pathologies. The fundamental challenge now is to understand the causal dimension of these relationships.</p>
</sec>
<sec id="s4">
<title>Overview of the Epidemiology of the Gut Microbiota-Cholesterolemia Relationship</title>
<p>Recent data from epidemiological studies report associations between phylum, bacterial taxa, and cholesterolemia (<xref ref-type="bibr" rid="B89">Koren et al., 2011</xref>; <xref ref-type="bibr" rid="B80">Karlsson et al., 2013</xref>; <xref ref-type="bibr" rid="B91">Le Chatelier et al., 2013</xref>; <xref ref-type="bibr" rid="B52">Fu et al., 2015</xref>) (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>). These data are based on microbial taxonomy derived from 16S rRNA gene sequencing (<xref ref-type="bibr" rid="B80">Karlsson et al., 2013</xref>; <xref ref-type="bibr" rid="B52">Fu et al., 2015</xref>) or whole-genome shotgun sequencing of microbial genes collectively present in feces (<xref ref-type="bibr" rid="B80">Karlsson et al., 2013</xref>; <xref ref-type="bibr" rid="B91">Le Chatelier et al., 2013</xref>), methods that reflect the current state of the art. However, these repertoires of genes or bacterial species do not make it possible to directly report microbial functions, which can vary considerably from one strain to another within the same species. Besides, the repertoire of genes identified at the bacterial DNA level does not necessarily reflect the repertoire of functions that can or will be expressed in the host. Nevertheless, cross-validation analysis on fecal taxonomy and on circulating lipid and lipoprotein levels from 893 individuals of the general Dutch population support a contribution of the microbiome to 1.5% of the variance in TC and 0.7% in LDL-C regardless of age, gender, and genetics, with the family of <italic>Clostridiaceae/Lachnospiracease</italic>
<italic>families</italic> being specifically associated with LDL-C (<xref ref-type="bibr" rid="B52">Fu et al., 2015</xref>). Comparable results are found by whole-genome analysis approaches on the same cohort enlarged up to 1135 individuals (<xref ref-type="bibr" rid="B187">Zhernakova et al., 2016</xref>). Of note, this population is primarily composed of normolipidemic subjects displaying a mean TC and LDL-C of 1.97 ± 0.39g/L and 1.24 ± 0.36g/L, respectively. These convergent data indicate that circulating concentrations of TC and LDL-C are correlated with changes in microbiota composition, and a recent study conducted on the LifeLines-DEEP cohort (1293 subjects) supports this hypothesis. In this study, 92 plasma proteins associated with CV risk were quantified. Among them, the variance in the concentration of circulating LDL receptor is explained by microbial factors for 5%, while only 0.1% is explained by genetic factors (quantitative trait locus) (<xref ref-type="bibr" rid="B188">Zhernakova et al., 2018</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>List of major clinical evidence.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th colspan="1" rowspan="1" valign="top">Evidence</th>
<th align="center" colspan="1" rowspan="1" valign="top">Cohort</th>
<th align="center" colspan="1" rowspan="1" valign="top">Correlation<break></break>Association</th>
<th align="center" colspan="1" rowspan="1" valign="top">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="4" valign="top">
<bold>Epidemiological</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">268 healthy subjects<break></break>(16S)</td>
<td colspan="1" rowspan="1" valign="top">Enterotypes/<break></break>Cholesterol</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B35">de Moraes et al., 2017</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">896 healthy subjects<break></break>(16S)</td>
<td colspan="1" rowspan="1" valign="top">Phylum/<break></break>Cholesterol</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B52">Fu et al., 2015</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">1135 healthy subjects (MGS)</td>
<td colspan="1" rowspan="1" valign="top">Taxa/<break></break>Cholesterol</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B187">Zhernakova et al., 2016</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Metabolic Syndrome<break></break>(MGS)</td>
<td colspan="1" rowspan="1" valign="top">Fecal microbial gene<break></break>richness and diversity/Cholesterol</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B80">Karlsson et al., 2013</xref>)<break></break>(<xref ref-type="bibr" rid="B91">Le Chatelier et al., 2013</xref>)</td>
</tr>
<tr>
<th colspan="1" rowspan="1" valign="top"></th>
<td align="left" colspan="1" rowspan="1" valign="top">Dyslipidemic cohort</td>
<td colspan="1" rowspan="1" valign="top">nd</td>
<td align="center" colspan="1" rowspan="1" valign="top">nd</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Dietary intervention</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">49 overweight/<break></break>obese adults (MGS)</td>
<td colspan="1" rowspan="1" valign="top">Fecal microbial gene richness/<break></break>LDL-C</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B30">Cotillard et al., 2013</xref>)<break></break>(<xref ref-type="bibr" rid="B32">Dao et al., 2016</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>nd, not done.</p>
</table-wrap-foot>
</table-wrap>
<p>In patients with metabolic syndrome, interindividual variations in circulating TC and LDL-C are associated with microbial gene richness and diversity (<xref ref-type="bibr" rid="B91">Le Chatelier et al., 2013</xref>). The correction of diversity loss after nutritional intervention in dysmetabolic patients corrects hypercholesterolemia (<xref ref-type="bibr" rid="B30">Cotillard et al., 2013</xref>) and is associated with a higher abundance of <italic>Akkermansia muciniphila</italic> (<xref ref-type="bibr" rid="B32">Dao et al., 2016</xref>) (<xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>). When hypercholesterolemia coexists with obesity, hypertension, and glucose intolerance, it should be taken into account that multiple mechanisms can contribute to the regulation of cholesterolemia, including pathways through which these pathologies are associated collectively (metabolic syndrome) or individually with dysbiosis (<xref ref-type="bibr" rid="B158">Ussar et al., 2015</xref>; <xref ref-type="bibr" rid="B99">Lim et al., 2017</xref>; <xref ref-type="bibr" rid="B70">Hoyles et al., 2018</xref>). Finally, a study in patients displaying clinical features of atherosclerosis in comparison with control subjects found associations between TC, LDL-C, and the oral abundance of some bacterial species (<xref ref-type="bibr" rid="B89">Koren et al., 2011</xref>).</p>
<p>Interestingly, studies performed in pigs, which have a metabolism and microbiome much closer to humans than rodent models, showed a significant contribution of the caecal microbiome of 5.6% to TC and of 2.8% to LDL-C (<xref ref-type="bibr" rid="B71">Huang et al., 2017</xref>). Additionally, most microbial taxa positively associated with TC and LDL-C belong to the pathogenic bacteria. These data are consistent with the known relationship between inflammation and serum cholesterol (<xref ref-type="bibr" rid="B83">Khovidhunkit et al., 2004</xref>), which needs to be further explored.</p>
<p>Although obtained in general populations, the influence of the gut microbiota on cholesterol levels would undoubtedly benefit from an investigation in a dyslipidemic cohort where reciprocal effects of hypercholesterolemia on microbiota functions may amplify dysbiosis and its consequences on host metabolism. Indeed, such correlative data do not establish a causal link. A disease may modify the gut microbiota, and conversely, the gut microbiota may trigger or aggravate a condition. Additionally, the bacterial species distribution is not homogeneous along the digestive tract, and fecal microbiota mostly reflects colonic species. Thus, feces analysis neglects the potential involvement of commensal species of the small intestine in dysbiosis, though this represents an essential site for the metabolism of cholesterol. Therefore, evaluation of the contribution of the microbiota to cholesterol levels is not optimal. In a recent study, albeit in a small cohort, the authors show that in hyperlipidemic patients, the higher prevalence of small intestinal bacterial overgrowth (SIBO) is positively associated with LDL-C levels (<xref ref-type="bibr" rid="B90">Kvit et al., 2019</xref>).</p>
</sec>
<sec id="s5">
<title>Modulation of the Microbiota and Its Impact on Cholesterolemia in Humans</title>
<p>After birth primo-colonization of the digestive tract, the gut microbiota becomes richer and more diversified all through life as a result of environmental challenges such as those from nutritional status, cultural habits, and drug treatments (<xref ref-type="bibr" rid="B130">Rothschild et al., 2018</xref>). Thus, the effect of changes in diet composition, eating patterns, on cholesterolemia is likely related to the benefits of prebiotics (<xref ref-type="bibr" rid="B11">Beserra et al., 2015</xref>) or a Mediterranean (<xref ref-type="bibr" rid="B50">Filippis et al., 2016</xref>) or vegan (versus omnivorous) (<xref ref-type="bibr" rid="B178">Wu et al., 2016</xref>) diet, which correlate with variations in microbiota composition. Likewise, lipids are strongly modified at birth and at weaning, two periods associated with major changes in microbial composition (<xref ref-type="bibr" rid="B117">Nuriel-Ohayon et al., 2016</xref>) and bile acid (BA) metabolism (<xref ref-type="bibr" rid="B75">Jönsson et al., 1995</xref>), which can influence circulating lipid and lipoprotein concentrations (<xref ref-type="bibr" rid="B76">Joyce et al., 2014</xref>). When administered orally, antibiotics induce a reduction in circulating cholesterol, which is strongly associated with changes in the composition of microbiota-derived secondary BAs (<xref ref-type="bibr" rid="B132">Samuel and Whithe, 1961</xref>; <xref ref-type="bibr" rid="B131">Samuel et al., 1973</xref>; <xref ref-type="bibr" rid="B112">Miettinen, 1979</xref>).</p>
</sec>
<sec id="s6">
<title>Gut Microbiota and Cholesterol Traits in Preclinical Models</title>
<p>Numerous studies that specifically evaluated the potential role of the microbiota in the regulation of cholesterol homeostasis have been conducted by using conventional approaches to eradicate the microbiota by either antibiotic therapy or an axenization procedure. These latter studies revealed that the absence of microbiota significantly influences cholesterolemia (<xref ref-type="table" rid="T2">
<bold>Table 2</bold>
</xref>). However, these associations are not all consistent in the normolipidemic context. Some teams show decreases in TC (<xref ref-type="bibr" rid="B123">Rabot et al., 2010</xref>) (<xref ref-type="bibr" rid="B163">Velagapudi et al., 2010</xref>; <xref ref-type="bibr" rid="B76">Joyce et al., 2014</xref>; <xref ref-type="bibr" rid="B189">Zhong et al., 2015</xref>), while others find no effect (<xref ref-type="bibr" rid="B31">Danielsson and Gustafsson, 1959</xref>; <xref ref-type="bibr" rid="B135">Sayin et al., 2013</xref>; <xref ref-type="bibr" rid="B119">Out et al., 2015</xref>; <xref ref-type="bibr" rid="B20">Caesar et al., 2016</xref>; <xref ref-type="bibr" rid="B113">Mistry et al., 2017</xref>; <xref ref-type="bibr" rid="B184">Zarrinpar et al., 2018</xref>) or even an increase (<xref ref-type="bibr" rid="B31">Danielsson and Gustafsson, 1959</xref>; <xref ref-type="bibr" rid="B20">Caesar et al., 2016</xref>). The potential underlying explanations of such variability involve (i) differences in microbiota composition between the animal facilities, (ii) normolipidemic wild type mice carry the majority of plasma cholesterol in HDL, (iii) reduced penetrance of the influence of the microbiota in a homeostatic context, as observed in the general human population (<xref ref-type="bibr" rid="B52">Fu et al., 2015</xref>). By contrast, in a commonly used mouse model of dyslipidemia (apolipoprotein-E and Ldl-r deficient mice), almost all studies show increased cholesterol levels in the absence of gut-microbiota (<xref ref-type="table" rid="T2">
<bold>Table 2</bold>
</xref>) (<xref ref-type="bibr" rid="B177">Wright et al., 2000</xref>; <xref ref-type="bibr" rid="B145">Stepankova et al., 2010</xref>; <xref ref-type="bibr" rid="B26">Chen et al., 2016</xref>; <xref ref-type="bibr" rid="B81">Kasahara et al., 2017</xref>; <xref ref-type="bibr" rid="B100">Lindskog Jonsson et al., 2018</xref>; <xref ref-type="bibr" rid="B85">Kiouptsi et al., 2019</xref>; <xref ref-type="bibr" rid="B92">Le Roy et al., 2019</xref>). The lipid-rich environment is associated with an impoverishment of gut microbiota diversity and richness (<xref ref-type="bibr" rid="B105">Martínez et al., 2013</xref>; <xref ref-type="bibr" rid="B15">Bo et al., 2017</xref>; <xref ref-type="bibr" rid="B156">Tran et al., 2019</xref>), increased intestinal barrier permeability, and endotoxemia (<xref ref-type="bibr" rid="B114">Netto Candido et al., 2018</xref>; <xref ref-type="bibr" rid="B136">Schoeler and Caesar, 2019</xref>; <xref ref-type="bibr" rid="B174">Wisniewski et al., 2019</xref>). Thus, in this inflammatory context, the influence of microbiota on cholesterolemia is revealed, as suggested by data obtained in the pig model (<xref ref-type="bibr" rid="B71">Huang et al., 2017</xref>). These findings are in agreement with data obtained in rodent models in which hypercholesterolemia associated with acute activation of innate immune receptors by endotoxin/lipopolysaccharide (LPS) is connected with an increase hepatic cholesterol synthesis and VLDL production and decreased VLDL and LDL clearance (also termed the lipemia of sepsis) (<xref ref-type="bibr" rid="B62">Harris et al., 2000</xref>). The underlying molecular mechanisms involve decreased nuclear receptor signaling of peroxisome proliferator-activated receptor (PPAR), liver X receptor (LXR), farnesoid X receptor (FXR), and retinoid X receptor (RXR) (<xref ref-type="bibr" rid="B83">Khovidhunkit et al., 2004</xref>). It additionally involves inhibition of reverse cholesterol transport (RCT) at multiple points, including decreased hepatic production of apolipoprotein A1, cholesterol ester transfer protein (CETP), ATP binding cassette transporters ABCG5 and ABCG8, and Cyp7a1. These findings are consistent with the association found of the lipopolysaccharide receptor Toll-like receptor 4 (TLR4) and NIMA‐related kinase 7 (NEK7) polymorphisms with LDL-C in human (<xref ref-type="bibr" rid="B190">Zhu et al., 2015</xref>; <xref ref-type="bibr" rid="B56">Gomes Torres et al., 2019</xref>). NEK7 is a serine/threonine kinase required for NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome assembly. However, this relationship should be tempered as chronic TLR-signaling deficiency in MyD88<sup>-/-</sup>/Apoe<sup>-/-</sup> (<xref ref-type="bibr" rid="B13">Björkbacka et al., 2004</xref>) (<xref ref-type="bibr" rid="B110">Michelsen et al., 2004</xref>), TLR4<sup>-/-</sup>/Ldl-r<sup>-/-</sup>, (<xref ref-type="bibr" rid="B49">Ferreira et al., 2015</xref>), TLR2<sup>-/-</sup>/Apoe<sup>-/-</sup>, and TLR4<sup>-/-</sup>/Apoe<sup>-/-</sup> (<xref ref-type="bibr" rid="B65">Higashimori et al., 2011</xref>) mice is not associated with changes in cholesterol levels as compared to control mice. It should also be noted that the evidence for the role of microbiota in genetically modified mice is difficult to interpret, as numerous studies in the literature do not report the experimental conditions (production of experimental groups, use of littermates, housing conditions). Indeed, fecal microbiota is partially normalized by extended co-housing conditions, due to coprophagic and grooming behaviors, thus abrogating microbiota-genotype dependent phenotype.</p>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p>List of major pre-clinical evidence.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th colspan="1" rowspan="1" valign="top">Model</th>
<th align="center" colspan="1" rowspan="1" valign="top">Diet</th>
<th align="center" colspan="1" rowspan="1" valign="top">Phenotype in germ-free</th>
<th align="center" colspan="1" rowspan="1" valign="top">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">
<bold>Axenic Normolipidemic</bold>
<break></break>
<bold>Rat</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">CD</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g004.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B31">Danielsson and Gustafsson, 1959</xref>)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">CD with 0.5% cholesterol</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g003.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B31">Danielsson and Gustafsson, 1959</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" valign="top">
<bold>Axenic</bold>
<break></break>
<bold>Normolipidemic</bold>
<break></break>
<bold>Mice</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">HFD<break></break>0.03% cholesterol</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g005.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B123">Rabot et al., 2010</xref>)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">CD*</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g006.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B163">Velagapudi et al., 2010</xref>)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">CD</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g009.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B135">Sayin et al., 2013</xref>)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">WD with 0.2% cholesterol</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g008.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B189">Zhong et al., 2015</xref>)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">CD source of fat: lard</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g017.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B20">Caesar et al., 2016</xref>)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">CD source of fat: fish oil</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g018.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B20">Caesar et al., 2016</xref>)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">CD</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g019.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B113">Mistry et al., 2017</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="4" valign="top">
<bold>Normolipidemic</bold>
<break></break>
<bold>Mice</bold>
<break></break>
<bold>(axenization by</bold>
<break></break>
<bold>a mixture of antibiotics)</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">CD*</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g012.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B76">Joyce et al., 2014</xref>)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">CD</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g024.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B119">Out et al., 2015</xref>)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">CD</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g025.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B184">Zarrinpar et al., 2018</xref>)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">CD</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g026.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Personal observations</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="9" valign="top">
<bold>Axenic</bold>
<break></break>
<bold>Dyslipidemic</bold>
<break></break>
<bold>Mice</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">Apoe<sup>-/-</sup> 0.15% cholesterol diet</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g027.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<xref ref-type="bibr" rid="B177">Wright et al., JEM 2000</xref>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">Apoe<sup>-/-</sup> CD</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g007.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B145">Stepankova et al., 2010</xref>)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">Apoe<sup>-/-</sup> 2% cholesterol</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g010.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B145">Stepankova et al., 2010</xref>)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">Apoe<sup>-/-</sup> CD</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g011.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B81">Kasahara et al., 2017</xref>)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">Apoe<sup>-/-</sup> CD</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g013.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B100">Lindskog Jonsson et al., 2018</xref>)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">Apoe<sup>-/-</sup> WD</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g020.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B100">Lindskog Jonsson et al., 2018</xref>)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">Ldlr<sup>-/-</sup> CD</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g014.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B85">Kiouptsi et al., 2019</xref>)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">Ldlr<sup>-/-</sup> 0.2% cholesterol diet</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g022.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B85">Kiouptsi et al., 2019</xref>)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">Apoe<sup>-/-</sup> CD</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g015.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B26">Chen et al., 2016</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="3" valign="top">
<bold>Dyslipidemic</bold>
<break></break>
<bold>Mice</bold>
<break></break>
<bold>(axenization by</bold>
<break></break>
<bold>a mixture of antibiotics)</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">Apoe<sup>-/-</sup> 0.15% cholesterol diet</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g016.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B26">Chen et al., 2016</xref>)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">Apoe<sup>-/-</sup> CD</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g021.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B92">Le Roy et al., 2019</xref>)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="top">Ldlr<sup>-/-</sup> CD</td>
<td align="center" colspan="1" rowspan="1" valign="top">Chol <inline-graphic mime-subtype="tiff" mimetype="image" xlink:href="fphar-11-00278-g023.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B92">Le Roy et al., 2019</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Dyslipidemic</bold>
<break></break>
<bold>Mice</bold>
<break></break>
<bold>FMT</bold>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">Apoe<sup>-/-</sup> CD</td>
<td align="center" colspan="1" rowspan="1" valign="top">Cholesterol levels transmitted**</td>
<td align="left" colspan="1" rowspan="1" valign="top">(<xref ref-type="bibr" rid="B92">Le Roy et al., 2019</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>All studies involved mice of C57Bl6 genetic background, except for two studies that used Swiss Webster mice (indicated by *). CD, chow diet; HFD, high-fat diet; WD, western diet; FMT, fecal material transfer.</p>
<p>**Phenotype in recipient mice.</p>
<p>↗Increased; ↘decreased; →no changes.</p>
</table-wrap-foot>
</table-wrap>
<p>Finally, using a standardized method, our recent work (<xref ref-type="bibr" rid="B92">Le Roy et al., 2019</xref>) demonstrates the microbiota-dependent transmissibility of a significant proportion of the cholesterol level (around 15-20%). Indeed, transplantation of the microbiota from hypercholesterolemic (without known genetic cause) human donors into recipient mice is sufficient to transfer the phenotype compared to the same experiment performed with normolipidemic donors. The more hypercholesterolemic phenotype is associated with “low hepatic cholesterol synthesis” and “high intestinal cholesterol absorption” traits in recipient mice. Several bacterial phylotypes affiliated with <italic>Beta-proteobacteria phylum</italic>, <italic>Alistipes genus, and Barnesiella genus</italic> were enriched in hypercholesterolemic mouse recipients. Similarly, <italic>Alistipes</italic> were recently associated with TC and LDL-C in HFD-fed hamsters treated with a chitin9-derived polysaccharide (chitosan) (<xref ref-type="bibr" rid="B155">Tong et al., 2019</xref>).</p>
<p>It is also of particular clinical interest to show the influence of the intestinal microbiota on the balance between absorption and cholesterol synthesis (<xref ref-type="bibr" rid="B92">Le Roy et al., 2019</xref>) since it has been observed in human cohorts that “high absorption” and “low synthesis” patterns are associated with higher LDL-C levels and are predictive of cardiovascular events (<xref ref-type="bibr" rid="B107">Matthan et al., 2009</xref>; <xref ref-type="bibr" rid="B139">Silbernagel et al., 2010</xref>; <xref ref-type="bibr" rid="B169">Weingärtner et al., 2011</xref>). Thus, inter-individual evaluation of microbiota diversity or dysbiosis opened up new opportunities for better therapeutic decision-making in ASCVD.</p>
</sec>
<sec id="s7">
<title>Gut Bacterial Metabolites, the New Frontier for Defining Pathological Metabolotypes</title>
<sec id="s7_1">
<title>Primary Bile Acids</title>
<p>Bile acid (BA) biosynthesis is the predominant metabolic pathway for cholesterol catabolism in the human body. The conversion of cholesterol to bile acids is a process performed by a set of hepatic enzymes necessary for the conversion of the steroid nucleus of cholesterol, the elimination of the side chain, amidation on the side chain with either glycine or taurine (GCA, GCDA, TCA, TCDCA) and eventually sulfonation or glucuronidation in the steroid backbone (<xref ref-type="bibr" rid="B68">Hofmann and Hagey, 2014</xref>). Another critical aspect of BA physiology is their circulation in the enterohepatic cycle, a finely tuned and orchestrated system, in which BAs synthesized in the liver are actively transported in the bile ducts, stored in the gallbladder, then secreted in the duodenum, absorbed again in the ileum, and recaptured by the liver <italic>via</italic> the portal circulation. Each stage of this enterohepatic cycle is influenced by diet, hormonal cross-regulation, and bacterial activities that maintain a functional and non-toxic supply of bile acids in circulation. Indeed, BAs have a pro-inflammatory and cytotoxic potential when they are not regulated, due to their detergent activity and destabilization of membranes, as shown in cholestatic liver diseases (<xref ref-type="fig" rid="f1">
<bold>Figure 1</bold>
</xref>).</p>
<fig id="f1" position="float">
<label>Figure 1</label>
<caption>
<p>Schematic view of host-gut microbial co-metabolism of bile acids and cholesterol in enterohepatic circulation.</p>
</caption>
<graphic xlink:href="fphar-11-00278-g001"></graphic>
</fig>
<p>In the post-prandial period, primary BAs are released into the intestinal lumen. Due to their amphiphilic properties, primary BAs adsorb at an oil–water interface to form mixed micelles with other bile lipids (cholesterol, phosphatidylcholine), fat-soluble vitamins (such as vitamins A, D, E, and K) and lipolysis products (free fatty acids, 2-monoglycerides). In the absence of bile secretion, fat absorption is impaired (<xref ref-type="bibr" rid="B67">Hofmann, 1999</xref>; <xref ref-type="bibr" rid="B33">Dawson and Karpen, 2015</xref>). In the ileum, a highly efficient transporter system allows active reabsorption of conjugated-BAs redirected to the liver through mesenteric and hepatic portal veins (<xref ref-type="bibr" rid="B33">Dawson and Karpen, 2015</xref>). At each enterohepatic cycle (4-5 cycles per day), about 5% of the non-absorbed BAs are released into the colon, modified by bacteria, and then excreted. This represents around 600 mg per day, the loss of which is compensated for by an equivalent synthesis from hepatic cholesterol. The co-excretion of fecal sterols and BAs in a 2:1 ratio in humans therefore represents a significant pathway for regulating cholesterol homeostasis (<xref ref-type="bibr" rid="B59">Groen et al., 2014</xref>).</p>
</sec>
<sec id="s7_2">
<title>Secondary Bile Acids</title>
<p>Another complexity in BA metabolism is the modification of the BA structure by intestinal bacteria (<xref ref-type="bibr" rid="B126">Ridlon et al., 2014</xref>). BAs that are not reabsorbed encounter anaerobic resident bacteria in the colon (<xref ref-type="fig" rid="f1">
<bold>Figure 1</bold>
</xref>). Microbial enzymes such as bile salt hydrolases (BSH) deconjugate conjugated -BAs, bacterial 7 α-dehydroxylases and 7 β-dehydroxylases convert CA and CDCA to deoxycholic acid (DCA) and lithocholic acid (LCA), respectively. Bacterial 7β-isomerization of the 7α-hydroxyl group of CDCA forms ursodeoxycholic acid (UDCA). Sulfated and glucuronidated BAs formed during hepatic detoxification to facilitate their urinary and fecal excretion can be hydrolyzed of their ester linkage by microbial enzymes (<xref ref-type="bibr" rid="B151">Takikawa et al., 1983</xref>; <xref ref-type="bibr" rid="B54">Gérard, 2013</xref>), ultimately leading to the presence of a vast repertoire of secondary BAs. In the colon, unconjugated BAs produced by microbial metabolism can diffuse passively over the intestinal border and can eventually be captured by the liver through multispecific organic anion-transporting polypeptide (OATP) transporters that can vehicle unconjugated BAs (Unconj-BA) and sulfated BAs (<xref ref-type="bibr" rid="B33">Dawson and Karpen, 2015</xref>). In the liver, conjugated BAs are more efficiently recycled from portal blood at the hepatic basolateral membrane by the high-affinity sodium-dependent taurocholate cotransporting polypeptide (NTCP) than are unconjugated BAs (<xref ref-type="bibr" rid="B5">Angelin et al., 1982</xref>; <xref ref-type="bibr" rid="B68">Hofmann and Hagey, 2014</xref>; <xref ref-type="bibr" rid="B43">Eggink et al., 2018</xref>). The estimated hepatic fractional uptake of total BAs ranges from 50 to 90% depending on the bile acid structure (<xref ref-type="bibr" rid="B5">Angelin et al., 1982</xref>) and is reflected by differences in systemic blood concentration versus portal blood concentration (<xref ref-type="bibr" rid="B43">Eggink et al., 2018</xref>). During the completion of the enterohepatic cycle, unamidated BAs can be conjugated again in the liver, leading to the formation of their glycine or taurine conjugates (GDCA, GLCA, GUDCA, TDCA, TLCA, and TUDCA), while CDCA and LCA can be 6α-hydroxylated to form hyocholic acid (HCA) and hyodeoxycholic acid (HDCA), respectively (<xref ref-type="bibr" rid="B16">Bodin et al., 2005</xref>). UDCA represents about 4% of total fecal BAs, and a cholesterol-lowering effect has been reported in patients with primary biliary cirrhosis (<xref ref-type="bibr" rid="B122">Poupon et al., 1993</xref>) or hypercholesterolemia (<xref ref-type="bibr" rid="B19">Cabezas Gelabert, 2004</xref>). Other exclusively microbial activities, including esterification, oxidation, and desulfation, contribute to the high chemical diversity and changes in hydrophobicity (<xref ref-type="bibr" rid="B126">Ridlon et al., 2014</xref>; <xref ref-type="bibr" rid="B39">Devlin and Fischbach, 2015</xref>; <xref ref-type="bibr" rid="B168">Watanabe et al., 2017</xref>) and bile acid signaling activities (<xref ref-type="bibr" rid="B154">Thomas et al., 2008</xref>; <xref ref-type="bibr" rid="B34">de Boer et al., 2018</xref>) (<xref ref-type="fig" rid="f1">
<bold>Figure 1</bold>
</xref>).</p>
<p>It should be noted that molecular species of BAs are involved not only in lipid metabolism but also in carbohydrate metabolism, energy homeostasis, and host immune responses through their agonistic or antagonistic activities on diverse receptors, the best characterized being the farnesoid X nuclear receptor (FXR) and the TGR5 membrane receptor (<xref ref-type="bibr" rid="B154">Thomas et al., 2008</xref>; <xref ref-type="bibr" rid="B34">de Boer et al., 2018</xref>); these aspects have been extensively reviewed elsewhere (<xref ref-type="bibr" rid="B69">Houten et al., 2006</xref>; <xref ref-type="bibr" rid="B154">Thomas et al., 2008</xref>; <xref ref-type="bibr" rid="B93">Lefebvre et al., 2009</xref>). Basically, FXR impacts cholesterolemia through the repression of CYP7A1, the rate-limiting enzyme that catabolizes conversion of cholesterol into BAs, resulting in decreased hepatic cholesterol content, followed by upregulation of the LDL-receptor expression and activity, which consequently reduces plasma LDL-C levels. This mechanism underlies the hypocholesterolemic effect of BAs sequestrants (<xref ref-type="bibr" rid="B143">Spinelli et al., 2016</xref>). Administration of obeticholic acid (FXR agonist) to chow-fed mice elevates liver LDL receptor expression by mRNA stabilization and reduces plasma LDL-C in mice (<xref ref-type="bibr" rid="B140">Singh et al., 2018</xref>). Of note, a recent study discovered a novel association of a variant in human NR1H4 gene (encoding the BA receptor FXR) with levels of TC and LDL-C (<xref ref-type="bibr" rid="B36">Deaton et al., 2018</xref>), thus highlighting the role of FXR in the regulation of plasma cholesterol levels in humans.</p>
<p>In the context of cholesterol reduction following antibiotic treatment, in humans (<xref ref-type="bibr" rid="B73">Jenkins et al., 2005</xref>), the prevailing hypothesis is that inhibition of the conversion of primary BAs to secondary BAs reduces their hydrophobicity, which results in poorer reabsorption by passive diffusion through the colonic epithelium. Similarly, this decrease in hydrophobicity of BAs is associated with a poorer micellization of cholesterol, which would, therefore, be less efficiently absorbed. These joint activities contribute to the outflow of BAs and cholesterol in the stool and therefore to a decreased sterol pool of the whole body. However, in humans, other molecular mechanisms must coexist to the extent that treatments with primary bile acids (CDCA) or secondary bile acid (LCA) only slightly alter the absorption of cholesterol and the serum concentrations of LDL-C (<xref ref-type="bibr" rid="B166">Wang et al., 2006</xref>). Other putative mechanisms qualitatively and quantitatively modulating the pool of bile acids may be at work; a pool of depleted BAs will be associated with the proliferation of pro-inflammatory microbes (<xref ref-type="bibr" rid="B77">Kakiyama et al., 2013</xref>) and intestinal barrier dysfunction (<xref ref-type="bibr" rid="B78">Kang et al., 2017</xref>), and a pool reconstituted after transfer of fecal material or liver transplantation will correct endotoxemia (<xref ref-type="bibr" rid="B78">Kang et al., 2017</xref>; <xref ref-type="bibr" rid="B6">Bajaj et al., 2018</xref>) and lipidemia (<xref ref-type="bibr" rid="B78">Kang et al., 2017</xref>).</p>
<p>Interestingly, the treatment of 51 naive type-2 diabetic patients with an antidiabetic (acarbose: a tetra-saccharide inhibiting hydrolysis of carbohydrates in the upper intestine and thus reducing glucose absorption) led to improvements of glycemia and cholesterolemia (<xref ref-type="bibr" rid="B60">Gu et al., 2017</xref>). These changes were correlated with variations in plasma BA profiles. The primary-BA/secondary-BA ratio and UDCA and T-DCA concentrations were negatively correlated with plasma cholesterol. Accordingly, metagenomics analysis confirmed a lower capacity for 7α/β dehydroxylation of BAs after acarbose treatment. The relative abundances of baiE (rate-limiting enzyme for 7α-dehydroxylation) and baiI (7β-dehydratase) were significantly decreased after acarbose treatment. Phylogenic analysis established a strong inverse correlation between <italic>Lactobacillus rhamnosus</italic> and plasma cholesterol and LDL-C levels. Interestingly, decreases in plasma cholesterol levels associated with acarbose treatment were associated with a decline in <italic>allistipes</italic> spp., in accordance with recent studies (<xref ref-type="bibr" rid="B92">Le Roy et al., 2019</xref>; <xref ref-type="bibr" rid="B155">Tong et al., 2019</xref>).</p>
<p>In conclusion, the mechanisms underlying bile acid-cholesterol-lowering relationships remain largely undefined. The specific roles of bile acids <italic>in vivo</italic> remain difficult to disentangle, due to the large number of compounds and biological properties involved, including detergent and bactericidal activities and FXR signaling potential (<xref ref-type="fig" rid="f1">
<bold>Figure 1</bold>
</xref>). The picture is even more complex if we consider the newly involved receptors such as pregnane X receptor (PXR), vitamin D3 receptor (VDR), muscarinic acetylcholine receptors, and sphingosine 1-phosphate receptor (S1PR). In addition to qualitative parameters, it is also necessary to consider all the poorly known circadian and post-prandial quantitative variations of BAs that will need to be well-defined to better understand the impact of BAs on cholesterol homeostasis (<xref ref-type="bibr" rid="B61">Han et al., 2015</xref>).</p>
</sec>
<sec id="s7_3">
<title>Short-Chain Fatty Acids (SCFAs)</title>
<p>SCFAs are the main end-product produced by the bacterial fermentation of non-digestible dietary fibers in the caecum and proximal colon. Consumption of dietary fibers such as inulin, oat bran, and pectin is effectively associated with lower plasma cholesterol levels, with reductions in cholesterol level ranging from 0.5% to 2% per gram of intake (<xref ref-type="bibr" rid="B128">Ripsin et al., 1992</xref>). Fibers reduce both TC and LDL-C (<xref ref-type="bibr" rid="B325">Anderson and Chen, 1979</xref>) through increased BA excretion and decreased hepatic synthesis of cholesterol (<xref ref-type="bibr" rid="B159">Vahouny et al., 1980</xref>; <xref ref-type="bibr" rid="B74">Jenkins et al., 2010</xref>). Other potential mechanisms are related to the microbiota-dependent formation of SCFAs (acetate, propionate, butyrate) that are produced and can be used as a macronutrient source of energy. Alternatively, SCFAs can act as hormone-like signaling, entering the portal circulation to ultimately bind to G-protein-coupled receptors (GPR) in numerous cells (<xref ref-type="bibr" rid="B106">Maslowski et al., 2009</xref>) and inhibit the histone deacetylase (HDAC), resulting in numerous epigenetic modifications in targeted cells (<xref ref-type="bibr" rid="B127">Riggs et al., 1977</xref>; <xref ref-type="bibr" rid="B21">Candido, 1978</xref>).</p>
<p>Several studies have described the role of SCFAs on immunity (<xref ref-type="bibr" rid="B2">Aguilar et al., 2014</xref>) and its protective effects against cardiovascular disease (<xref ref-type="bibr" rid="B7">Bazzano et al., 2003</xref>; <xref ref-type="bibr" rid="B47">Fernandez et al., 2019</xref>), yet few of them have individually examined the effects on cholesterol levels. <italic>Ex vivo</italic> and <italic>in vivo</italic> studies have shown that acetate and butyrate (but not propionate) are potential precursors of cholesterol synthesis that can be incorporated into the endogenous cholesterol synthesis pathway (<xref ref-type="bibr" rid="B175">Wolever et al., 1991</xref>; <xref ref-type="bibr" rid="B37">Demigné et al., 1995</xref>; <xref ref-type="bibr" rid="B38">den Besten et al., 2013</xref>). By contrast, earlier studies reported inhibition of cholesterol synthesis by propionate through decreased expression of the HMGCS and HMGCR genes (<xref ref-type="bibr" rid="B18">Bush and Milligan, 1971</xref>; <xref ref-type="bibr" rid="B129">Rodwell et al., 1976</xref>; <xref ref-type="bibr" rid="B37">Demigné et al., 1995</xref>), white more recent studies have not confirmed such effects (<xref ref-type="bibr" rid="B186">Zhao et al., 2017</xref>). Accordingly, in healthy subjects, the oral administration of propionate does not lower plasma cholesterol but does increase HDL and triglycerides levels (<xref ref-type="bibr" rid="B164">Venter et al., 1990</xref>). In vivo, supplementation of a cholesterol-rich diet with acetate in rats resulted in a lower increase of TC levels associated with lower hepatic HMGCS and increased conversion of cholesterol into BAs due to the upregulation of Cyp7a (<xref ref-type="bibr" rid="B53">Fushimi et al., 2006</xref>). A similar rise in Cyp7a was observed in Apoe-deficient mice fed with a cholesterol-rich diet supplemented with butyrate, with additional beneficial effects on the “reverse cholesterol transport” (RCT) (<xref ref-type="bibr" rid="B41">Du et al., 2019</xref>). The connection between SCFAs and BAs metabolism was further reported in Syrian hamsters (<xref ref-type="bibr" rid="B186">Zhao et al., 2017</xref>). The addition of acetate, propionate, or butyrate to a cholesterol-rich diet resulted in decreased CT levels and LDL-C/HDL-C ratio and to increased fecal excretion of BAs (LCA, DCA, CDCA, CA). Expression of the SREBP2, LDLR, and CYP7A1 genes was also involved (<xref ref-type="bibr" rid="B186">Zhao et al., 2017</xref>). The effects of SCFAs were more specifically addressed in mice deficient for FFAR2/GPR43, one of the SCFA receptors (<xref ref-type="bibr" rid="B14">Bjursell et al., 2011</xref>). High-fat fed GPR43-deficient mice displayed lower CT levels than control mice.</p>
<p>Collectively, the role of SCFAs in cholesterol levels is poorly defined. SCFAs may be used as precursors of cholesterol synthesis, but the overall hypocholesterolemic effect seems to be associated with the conversion of cholesterol into BAs. Translation studies into humans will be critical to move forward (<xref ref-type="fig" rid="f2">
<bold>Figure 2</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure 2</label>
<caption>
<p>Schematic depicting the range of putative pathways through which the gut metabolites impact on cholesterol metabolism. Diet nutriments (green boxes) are metabolized and transformed into microbial metabolites (blue boxes) by gut microbiota. Purple boxes represent enzymes. Red boxes represent host metabolites. TMA, Trimethylamine; TMA-O, Trimethylamine-Oxide; SCFAs, Short Chain Fatty Acids; BAs, Bile Acids; IAA, Indole-3-acetic acid; IPA, Indole-3-propionic acid; IDO, indoleamine2,3-dioxygenase; 3-HAA, 3-hydroxyanthranilic; LPS, lipopolysaccharides.</p>
</caption>
<graphic xlink:href="fphar-11-00278-g002"></graphic>
</fig>
</sec>
<sec id="s7_4">
<title>Trimethylamine-oxide (TMA-O)</title>
<p>The contributing role of intestinal microbiota to ACV diseases through the production of trimethylamine-N-oxide (TMA-O, has been recently demonstrated (<xref ref-type="bibr" rid="B124">Randrianarisoa et al., 2016</xref>; <xref ref-type="bibr" rid="B153">Tang et al., 2017</xref>; <xref ref-type="bibr" rid="B179">Yang et al., 2019</xref>) and has been covered in recent reviews (<xref ref-type="bibr" rid="B17">Brown and Hazen, 2018</xref>; <xref ref-type="bibr" rid="B179">Yang et al., 2019</xref>). Essentially, trimethylamine-containing dietary nutrients (choline, phosphatidylcholine, γ-butyrobetaine, and carnitine) are metabolized by microbes, leading to the production of trimethylamine (TMA), which is rapidly converted by host hepatic flavin monooxygenase 3 (FMO3) into trimethylamine N-oxide (TMA-O). Interestingly, in dyslipidemic mouse models, TMA-O affects cholesterol homeostasis mainly by suppressing reverse cholesterol transport (RCT) (<xref ref-type="bibr" rid="B87">Koeth et al., 2013</xref>) and impacting the BA metabolic pathways at multiple levels (decreased expression of hepatic BAs synthetic enzymes (Cyp7a1 and Cyp27a1) and hepatic BA transporters (Oatp1, Oatp4, Mrp2, and Ntcp) (<xref ref-type="bibr" rid="B87">Koeth et al., 2013</xref>). Additionally, TMA-O appears to promote cholesterol uptake by macrophages by inducing scavenger receptors CD36 and SRA1, both of which are involved in the intracellular accumulation of modified lipoproteins (<xref ref-type="bibr" rid="B167">Wang et al., 2011</xref>). Likewise, under normal dietary conditions, TMA-O did not impact plasma cholesterol levels in mice deficient for FMO genes (<xref ref-type="bibr" rid="B161">Veeravalli et al., 2018</xref>). Identification of TMA-O receptors would be of particular interest to substantiate a potential association of TMA-O with cholesterol levels, albeit that no significant correlations between TMA-O and TC, LDL-C, even when excluding individuals taking cholesterol-lowering medications, have been observed (<xref ref-type="bibr" rid="B97">Li et al., 2017</xref>). This might explain why TMA-O has been demonstrated to be a prognostic marker for ACV diseases beyond traditional risk factors (<xref ref-type="bibr" rid="B104">Manor et al., 2018</xref>) (<xref ref-type="fig" rid="f2">
<bold>Figure 2</bold>
</xref>).</p>
</sec>
<sec id="s7_5">
<title>Diet-Associated Tryptophan (Trp) Derivatives</title>
<p>Tryptophan is an essential amino acid that is degraded through the kynurenine pathway, leading to the generation of several biologically active compounds. Endogenous kynurenine metabolites contribute to the initiation of ACV disease. In human atherosclerotic plaques, Trp metabolites were found to be associated with unstable plaque phenotype (<xref ref-type="bibr" rid="B152">Taleb, 2019</xref>). Tryptophan is processed 95% by the kynurenine pathway (gut-microbiota independent) and 5% by the indole pathway (gut microbiota-dependent). Regarding the kynurenin pathway, supplementation of 3-hydroxyanthranilic (3-HAA), a tryptophan-derivative metabolite from the kynurenine pathway has anti-atherosclerotic effects, associated with lower plasma cholesterol levels in Ldl-r-deficient mice fed an HFD regime (<xref ref-type="bibr" rid="B185">Zhang et al., 2012</xref>) or a western diet (<xref ref-type="bibr" rid="B10">Berg et al., 2019</xref>). Correspondingly, indoleamine 2,3-dioxygenase (IDO) inhibition showed the exact opposite phenotype in Apoe-deficient mice fed an HFD (<xref ref-type="bibr" rid="B121">Polyzos et al., 2015</xref>; <xref ref-type="bibr" rid="B98">Liang et al., 2019</xref>), while no effect was reported in chow-diet-fed double-deficient mice for Apoe and IDO (<xref ref-type="bibr" rid="B28">Cole et al., 2015</xref>). IDO enzymes are involved in the catabolism of tryptophan, and the ratio of kynurenine to tryptophan (kyn/trp) can be used to reflect IDO activity. In clinical investigations, IDO activity has been reported to be positively correlated with a range of atherosclerosis risk factors in the female population, including LDL-C (<xref ref-type="bibr" rid="B120">Pertovaara et al., 2007</xref>). Concerning the indole pathway, tryptophan, indole-3-propionic acid, and indole-3-aldehyde were shown to be decreased in atherosclerotic patients, while kynurenine/tryptophan ratios were increased (<xref ref-type="bibr" rid="B24">Cason et al., 2018</xref>); still, no independent correlation with cholesterol has yet been reported. In conclusion, the scarcity of studies does not allow the indole pathway to be implicated in regulation of cholesterolemia (<xref ref-type="fig" rid="f2">
<bold>Figure 2</bold>
</xref>).</p>
</sec>
</sec>
<sec id="s8">
<title>Conversion of Cholesterol Into Coprostanol</title>
<p>Cholesterol from the diet, bile, or intestinal cells is actively metabolized by intestinal bacteria, mainly in coprostanol (<xref ref-type="bibr" rid="B54">Gérard, 2013</xref>). Unlike cholesterol, coprostanol is very poorly absorbed by the intestine (<xref ref-type="bibr" rid="B12">Bhattacharyya, 1986</xref>). In a singular way, the rate of conversion of microbial cholesterol to coprostanol in the general human population appears to be multimodal, with an average of 65% of high converters (80% to 100% of luminal cholesterol is converted to coprostanol in the colon), 21% of intermediate converters and 14% of non-converters (<xref ref-type="bibr" rid="B171">Wilkins and Hackman, 1974</xref>; <xref ref-type="bibr" rid="B111">Midtvedt et al., 1990</xref>; <xref ref-type="bibr" rid="B162">Veiga et al., 2005</xref>; <xref ref-type="bibr" rid="B9">Benno et al., 2005</xref>). It was also demonstrated that this phenotypic characteristic was maintained in axenic rodents (without germs) colonized with a high-converter or non-converter human microbiota (<xref ref-type="bibr" rid="B55">Gérard et al., 2004</xref>). Finally, several clinical and preclinical studies support the hypothesis that the conversion of cholesterol in coprostanol could influence the bioavailability of cholesterol, leading to modulation of plasma cholesterol levels (<xref ref-type="bibr" rid="B137">Sekimoto et al., 1983</xref>; <xref ref-type="bibr" rid="B96">Li et al., 1995</xref>; <xref ref-type="bibr" rid="B95">Li et al., 1998</xref>). Larger studies are needed to validate this relationship. Notably, the disconnection between the major cholesterol uptake site (small intestine <italic>via</italic> the Niemann-Pick C1-Like 1 transporter (NPC1L1)) and the site of cholesterol conversion to coprostanol (colon) does not plead for a causal relationship. Nevertheless, normolipidemic subjects treated with Ezetimibe (NPC1L1 inhibitor) show residual absorption of cholesterol, which suggests as yet unidentified additional absorption mechanisms (<xref ref-type="bibr" rid="B72">Jakulj et al., 2016</xref>) (<xref ref-type="fig" rid="f1">
<bold>Figures 1</bold>
</xref> and <xref ref-type="fig" rid="f2">
<bold>2</bold>
</xref>).</p>
</sec>
<sec id="s9">
<title>Impact of the Microbiota on Hypocholesterolemic Drug Efficacy</title>
<p>The gut microbiota has been shown to impact, negatively or positively, drug efficacy. This effect has been shown to result either from modifications in pharmacokinetic or pharmacodynamic properties or by synergistic/antagonistic effect of microbiota toward drugs. As a matter of fact, the impact of the microbiota on drugs is not restrained to oral drug intake, as studies have shown modifications in monoclonal antibody efficacy (<xref ref-type="bibr" rid="B141">Sivan et al., 2015</xref>; <xref ref-type="bibr" rid="B40">Doherty et al., 2018</xref>). The interaction of gut microbiota with drug efficacy/toxicity has recently been exhaustively reported upon (<xref ref-type="bibr" rid="B142">Spanogiannopoulos et al., 2016</xref>; <xref ref-type="bibr" rid="B173">Wilson and Nicholson, 2017</xref>; <xref ref-type="bibr" rid="B27">Clarke et al., 2019</xref>).</p>
<p>Direct links between the gut microbiota and hypocholesterolemic drugs are still thin. Statins, which are the leading pharmaceutical class in hyperlipemia therapeutic care, are ineffective for almost 20% of patients treated and are sometimes even deleterious (<xref ref-type="bibr" rid="B147">Stroes et al., 2015</xref>). Several studies have explored and demonstrated that statins can directly influence the growth and virulence of bacterial pathogens and commensal bacteria as well as combating microbial infections, such as in sepsis and pneumonia (<xref ref-type="bibr" rid="B64">Hennessy et al., 2016</xref>; <xref ref-type="bibr" rid="B191">Zimmermann et al., 2019</xref>). The first statin, “Mevastatin,” which is a metabolic product of Penicillium citrinum, was initially characterized for its antibiotic properties, and statins are now considered as adjuvant antibiotics that can impact antimicrobial resistance (<xref ref-type="bibr" rid="B86">Ko et al., 2017</xref>). Consequently, the role of statins deserves to be explored beyond their traditionally established indications in light of their antimicrobial potential as a regulator of gastrointestinal microbiota (<xref ref-type="bibr" rid="B116">Nolan et al., 2017</xref>). Only a few studies have shown the impact of the microbiota on statin efficacy. Still, these studies suggested that the microbiota participated in statin’s effect (<xref ref-type="bibr" rid="B63">He et al., 2017</xref>) and was responsible for statin metabolization (<xref ref-type="bibr" rid="B180">Yoo et al., 2014</xref>) and that the microbiota from patients unresponsive to statin was different from that of responsive patients (<xref ref-type="bibr" rid="B148">Sun et al., 2018</xref>).</p>
<p>Additional studies are required in this context and should, therefore, also be conducted on other therapeutic classes of hypolipemic drugs. Understanding the impact of the microbiota on drug efficacy/toxicity should bring us closer to personalized medicine and should result in an improvement in therapeutic care.</p>
</sec>
<sec id="s10">
<title>Concluding Remarks</title>
<p>LDL-C is the primary target for the management of atherogenic dyslipidemia and the reduction of cardiovascular events. New actors such as the microbiota introduce more complexity into this multifactorial disease but allow new insight into pathogenicity and the development of new prevention and prophylaxis approaches. In addition to the usual pharmacological approaches (statins, ezetimibe, fibrates, resins, proprotein convertase subtilisin-kexin 9 (PCSK9) inhibitors), new biotherapies targeting the microbiota are possible. Indeed, the data in the literature support the notion that the microbiota has a causal contribution to the metabolism of lipoproteins and host cholesterol. The mechanisms of this reciprocal influence need to be clarified, and the advent of functional analyses of the microbiota, the development of new technologies allowing the culture of anaerobic microbes, and the advent of more and more better-performing technologies will make it possible to specify the dynamics of the relationship of the intestinal microbiota with cholesterol metabolism.</p>
</sec>
<sec id="s11">
<title>Author Contributions</title>
<p>RV, PK, SB, MS, DR, MG, and PL originally conceived and wrote the manuscript. All authors read and approved the final manuscript.</p>
</sec>
<sec id="s12" sec-type="funding-information">
<title>Funding</title>
<p>This study was supported by the Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU), and the Fondation de France (00029519). PK was a recipient of a research fellowship from the French Ministry of Research and Technology and from the New French Atherosclerosis Society (NSFA). MS is supported by a fellowship from the Mexican National Council of Science and Technology (CONACYT).</p>
</sec>
<sec id="s13">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abul-Husn</surname><given-names>N. S.</given-names></name><name><surname>Manickam</surname><given-names>K.</given-names></name><name><surname>Jones</surname><given-names>L. K.</given-names></name><name><surname>Wright</surname><given-names>E. A.</given-names></name><name><surname>Hartzel</surname><given-names>D. N.</given-names></name><name><surname>Gonzaga-Jauregui</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Genetic identification of familial hypercholesterolemia within a single U.S. health care system</article-title>. <source/>Science
<volume>354</volume>, aaf7000-1–aaf7000-7.  <pub-id pub-id-type="doi">10.1126/science.aaf7000</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aguilar</surname><given-names>E. C.</given-names></name><name><surname>Leonel</surname><given-names>A. J.</given-names></name><name><surname>Teixeira</surname><given-names>L. G.</given-names></name><name><surname>Silva</surname><given-names>A. R.</given-names></name><name><surname>Silva</surname><given-names>J. F.</given-names></name><name><surname>Pelaez</surname><given-names>J. M. N.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Butyrate impairs atherogenesis by reducing plaque inflammation and vulnerability and decreasing NFκB activation</article-title>. <source/>Nutr. Metab. Cardiovasc. Dis.
<volume>24</volume>, <fpage>606</fpage>–<lpage>613</lpage>.  <pub-id pub-id-type="doi">10.1016/j.numecd.2014.01.002</pub-id>
<pub-id pub-id-type="pmid">24602606</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Agus</surname><given-names>A.</given-names></name><name><surname>Planchais</surname><given-names>J.</given-names></name><name><surname>Sokol</surname><given-names>H.</given-names></name></person-group> (<year>2018</year>). <article-title>Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease</article-title>. <source/>Cell Host Microbe
<volume>23</volume>, <fpage>716</fpage>–<lpage>724</lpage>.  <pub-id pub-id-type="doi">10.1016/j.chom.2018.05.003</pub-id>
<pub-id pub-id-type="pmid">29902437</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Allayee</surname><given-names>H.</given-names></name><name><surname>Hazen</surname><given-names>S. L.</given-names></name></person-group> (<year>2015</year>). <article-title>Contribution of Gut Bacteria to Lipid Levels: Another Metabolic Role for Microbes</article-title>? <source/>Circ. Res.
<volume>117</volume>, <fpage>750</fpage>–<lpage>754</lpage>.  <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.307409</pub-id>
<pub-id pub-id-type="pmid">26450886</pub-id></mixed-citation>
</ref>
<ref id="B325">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anderson</surname><given-names>J. W.</given-names></name><name><surname>Chen</surname><given-names>W. J.</given-names></name></person-group> (<year>1979</year>). <article-title>Plant fibe1r. Carbohydrate and lipid metabolism</article-title>. <source/>Am. J. Clin. Nutr. <volume>32</volume> (<issue>2</issue>), <fpage>346</fpage>–<lpage>363</lpage>. <pub-id pub-id-type="doi">10.1093/ajcn/32.2.346</pub-id>
<pub-id pub-id-type="pmid">420130</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Angelin</surname><given-names>B.</given-names></name><name><surname>Björkhem</surname><given-names>I.</given-names></name><name><surname>Einarsson</surname><given-names>K.</given-names></name><name><surname>Ewerth</surname><given-names>S.</given-names></name></person-group> (<year>1982</year>). <article-title>Hepatic Uptake of Bile Acids in Man</article-title>. <source/>J. Clin. Invest.
<volume>70</volume>, <fpage>724</fpage>–<lpage>731</lpage>.  <pub-id pub-id-type="doi">10.1172/JCI110668</pub-id>
<pub-id pub-id-type="pmid">7119112</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bajaj</surname><given-names>J. S.</given-names></name><name><surname>Kakiyama</surname><given-names>G.</given-names></name><name><surname>Cox</surname><given-names>I. J.</given-names></name><name><surname>Nittono</surname><given-names>H.</given-names></name><name><surname>Takei</surname><given-names>H.</given-names></name><name><surname>White</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Alterations in gut microbial function following liver transplant</article-title>. <source/>Liver Transplant.
<volume>24</volume>, <fpage>752</fpage>–<lpage>761</lpage>.  <pub-id pub-id-type="doi">10.1002/lt.25046</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bazzano</surname><given-names>L. A.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Ogden</surname><given-names>L. G.</given-names></name><name><surname>Loria</surname><given-names>C. M.</given-names></name><name><surname>Whelton</surname><given-names>P. K.</given-names></name><collab>National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study</collab></person-group> (<year>2003</year>). <article-title>Dietary fiber intake and reduced risk of coronary heart disease in US men and women: the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study</article-title>. <source/>Arch. Intern. Med.
<volume>163</volume>, <fpage>1897</fpage>–<lpage>1904</lpage>.  <pub-id pub-id-type="doi">10.1001/archinte.163.16.1897</pub-id>
<pub-id pub-id-type="pmid">12963562</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benetti</surname><given-names>A.</given-names></name><name><surname>Del Puppo</surname><given-names>M.</given-names></name><name><surname>Crosignani</surname><given-names>A.</given-names></name><name><surname>Veronelli</surname><given-names>A.</given-names></name><name><surname>Masci</surname><given-names>E.</given-names></name><name><surname>Frigè</surname><given-names>F.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Cholesterol metabolism after bariatric surgery in grade 3 obesity: differences between malabsorptive and restrictive procedures</article-title>. <source/>Diabetes Care
<volume>36</volume>, <fpage>1443</fpage>–<lpage>1447</lpage>.  <pub-id pub-id-type="doi">10.2337/dc12-1737</pub-id>
<pub-id pub-id-type="pmid">23275360</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benno</surname><given-names>P.</given-names></name><name><surname>Midtvedt</surname><given-names>K.</given-names></name><name><surname>Alam</surname><given-names>M.</given-names></name><name><surname>Collinder</surname><given-names>E.</given-names></name><name><surname>Norin</surname><given-names>E.</given-names></name><name><surname>Midtvedt</surname><given-names>T.</given-names></name></person-group> (<year>2005</year>). <article-title>Examination of intestinal conversion of cholesterol to coprostanol in 633 healthy subjects reveals an age- and sex-dependent pattern</article-title>. <source/>Microb. Ecol. Health Dis.
<volume>17</volume>, <fpage>200</fpage>–<lpage>204</lpage>.  <pub-id pub-id-type="doi">10.1080/08910600500519854</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berg</surname><given-names>M.</given-names></name><name><surname>Polyzos</surname><given-names>K. A.</given-names></name><name><surname>Agardh</surname><given-names>H.</given-names></name><name><surname>Baumgartner</surname><given-names>R.</given-names></name><name><surname>Forteza</surname><given-names>M. J.</given-names></name><name><surname>Kareinen</surname><given-names>I.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>3-Hydroxyanthralinic acid Metabolism Controls the Hepatic Srebp/Lipoprotein axis, Inhibits Inflammasome Activation in Macrophages, and Decreases Atherosclerosis in LDLR-/- Mice</article-title>. <source/>Cardiovasc. Res.  <pub-id pub-id-type="doi">10.1093/cvr/cvz258</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beserra</surname><given-names>B. T. S.</given-names></name><name><surname>Fernandes</surname><given-names>R.</given-names></name><name><surname>do Rosario</surname><given-names>V. A.</given-names></name><name><surname>Mocellin</surname><given-names>M. C.</given-names></name><name><surname>Kuntz</surname><given-names>M. G. F.</given-names></name><name><surname>Trindade</surname><given-names>E. B. S. M.</given-names></name></person-group> (<year>2015</year>). <article-title>A systematic review and meta-analysis of the prebiotics and synbiotics effects on glycaemia, insulin concentrations and lipid parameters in adult patients with overweight or obesity</article-title>. <source/>Clin. Nutr. Edinb. Scotl.
<volume>34</volume>, <fpage>845</fpage>–<lpage>858</lpage>.  <pub-id pub-id-type="doi">10.1016/j.clnu.2014.10.004</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhattacharyya</surname><given-names>A. K.</given-names></name></person-group> (<year>1986</year>). <article-title>Differences in uptake and esterification of saturated analogues of cholesterol by rat small intestine</article-title>. <source/>Am. J. Physiol.
<volume>251</volume>, <fpage>G495</fpage>–<lpage>G500</lpage>.  <pub-id pub-id-type="doi">10.1152/ajpgi.1986.251.4.G495</pub-id>
<pub-id pub-id-type="pmid">3094380</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Björkbacka</surname><given-names>H.</given-names></name><name><surname>Kunjathoor</surname><given-names>V. V.</given-names></name><name><surname>Moore</surname><given-names>K. J.</given-names></name><name><surname>Koehn</surname><given-names>S.</given-names></name><name><surname>Ordija</surname><given-names>C. M.</given-names></name><name><surname>Lee</surname><given-names>M. A.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways</article-title>. <source/>Nat. Med.
<volume>10</volume>, <fpage>416</fpage>–<lpage>421</lpage>.  <pub-id pub-id-type="doi">10.1038/nm1008</pub-id>
<pub-id pub-id-type="pmid">15034566</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bjursell</surname><given-names>M.</given-names></name><name><surname>Admyre</surname><given-names>T.</given-names></name><name><surname>Göransson</surname><given-names>M.</given-names></name><name><surname>Marley</surname><given-names>A. E.</given-names></name><name><surname>Smith</surname><given-names>D. M.</given-names></name><name><surname>Oscarsson</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet</article-title>. <source/>Am. J. Physiol. Endocrinol. Metab.
<volume>300</volume>, <fpage>E211</fpage>–<lpage>E220</lpage>.  <pub-id pub-id-type="doi">10.1152/ajpendo.00229.2010</pub-id>
<pub-id pub-id-type="pmid">20959533</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bo</surname><given-names>T.</given-names></name><name><surname>Shao</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Niu</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>L.</given-names></name></person-group> (<year>2017</year>). <article-title>Relative variations of gut microbiota in disordered cholesterol metabolism caused by high-cholesterol diet and host genetics</article-title>. <source/>MicrobiologyOpen
<volume>6</volume>, <fpage>1</fpage>–<lpage>11</lpage>.  <pub-id pub-id-type="doi">10.1002/mbo3.491</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bodin</surname><given-names>K.</given-names></name><name><surname>Lindbom</surname><given-names>U.</given-names></name><name><surname>Diczfalusy</surname><given-names>U.</given-names></name></person-group> (<year>2005</year>). <article-title>Novel pathways of bile acid metabolism involving CYP3A4</article-title>. <source/>Biochim. Biophys. Acta BBA - Mol. Cell Biol. Lipids
<volume>1687</volume>, <fpage>84</fpage>–<lpage>93</lpage>.  <pub-id pub-id-type="doi">10.1016/j.bbalip.2004.11.003</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brown</surname><given-names>J. M.</given-names></name><name><surname>Hazen</surname><given-names>S. L.</given-names></name></person-group> (<year>2018</year>). <article-title>Microbial modulation of cardiovascular disease</article-title>. <source/>Nat. Rev. Microbiol.
<volume>16</volume>, <fpage>171</fpage>–<lpage>181</lpage>.  <pub-id pub-id-type="doi">10.1038/nrmicro.2017.149</pub-id>
<pub-id pub-id-type="pmid">29307889</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bush</surname><given-names>R. S.</given-names></name><name><surname>Milligan</surname><given-names>L. P.</given-names></name></person-group> (<year>1971</year>). <article-title>Study of the mechanism of inhibition of ketogenesis by propionate in bovine liver</article-title>. <source/>Can. J. Anim. Sci.
<volume>51</volume>, <fpage>121</fpage>–<lpage>127</lpage>.  <pub-id pub-id-type="doi">10.4141/cjas71-016</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cabezas Gelabert</surname><given-names>R.</given-names></name></person-group> (<year>2004</year>). [<article-title>Effect of ursodeoxycholic acid combined with statins in hypercholesterolemia treatment: a prospective clinical trial</article-title>]. <source/>Rev. Clin. Esp.
<volume>204</volume>, <fpage>632</fpage>–<lpage>635</lpage>.  <pub-id pub-id-type="doi">10.1016/s0014-2565(04)71566-0</pub-id>
<pub-id pub-id-type="pmid">15710069</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Caesar</surname><given-names>R.</given-names></name><name><surname>Nygren</surname><given-names>H.</given-names></name><name><surname>Orešič</surname><given-names>M.</given-names></name><name><surname>Bäckhed</surname><given-names>F.</given-names></name></person-group> (<year>2016</year>). <article-title>Interaction between dietary lipids and gut microbiota regulates hepatic cholesterol metabolism</article-title>. <source/>J. Lipid Res.
<volume>57</volume>, <fpage>474</fpage>–<lpage>481</lpage>.  <pub-id pub-id-type="doi">10.1194/jlr.M065847</pub-id>
<pub-id pub-id-type="pmid">26783361</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Candido</surname><given-names>E.</given-names></name></person-group> (<year>1978</year>). <article-title>Sodium butyrate inhibits histone deacetylation in cultured cells</article-title>. <source/>Cell
<volume>14</volume>, <fpage>105</fpage>–<lpage>113</lpage>.  <pub-id pub-id-type="doi">10.1016/0092-8674(78)90305-7</pub-id>
<pub-id pub-id-type="pmid">667927</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cani</surname><given-names>P. D.</given-names></name><name><surname>Knauf</surname><given-names>C.</given-names></name></person-group> (<year>2016</year>). <article-title>How gut microbes talk to organs: The role of endocrine and nervous routes</article-title>. <source/>Mol. Metab.
<volume>5</volume>, <fpage>743</fpage>–<lpage>752</lpage>.  <pub-id pub-id-type="doi">10.1016/j.molmet.2016.05.011</pub-id>
<pub-id pub-id-type="pmid">27617197</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cani</surname><given-names>P. D.</given-names></name><name><surname>Amar</surname><given-names>J.</given-names></name><name><surname>Iglesias</surname><given-names>M. A.</given-names></name><name><surname>Poggi</surname><given-names>M.</given-names></name><name><surname>Knauf</surname><given-names>C.</given-names></name><name><surname>Bastelica</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Metabolic endotoxemia initiates obesity and insulin resistance</article-title>. <source/>Diabetes
<volume>56</volume>, <fpage>1761</fpage>–<lpage>1772</lpage>.  <pub-id pub-id-type="doi">10.2337/db06-1491</pub-id>
<pub-id pub-id-type="pmid">17456850</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cason</surname><given-names>C. A.</given-names></name><name><surname>Dolan</surname><given-names>K. T.</given-names></name><name><surname>Sharma</surname><given-names>G.</given-names></name><name><surname>Tao</surname><given-names>M.</given-names></name><name><surname>Kulkarni</surname><given-names>R.</given-names></name><name><surname>Helenowski</surname><given-names>I. B.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Plasma microbiome-modulated indole- and phenyl-derived metabolites associate with advanced atherosclerosis and postoperative outcomes</article-title>. <source/>J. Vasc. Surg.
<volume>68</volume>, <fpage>1552</fpage>–<lpage>1562</lpage>.e7.  <pub-id pub-id-type="doi">10.1016/j.jvs.2017.09.029</pub-id>
<pub-id pub-id-type="pmid">29248242</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cerdá</surname><given-names>B.</given-names></name><name><surname>Pérez</surname><given-names>M.</given-names></name><name><surname>Pérez-Santiago</surname><given-names>J. D.</given-names></name><name><surname>Tornero-Aguilera</surname><given-names>J. F.</given-names></name><name><surname>González-Soltero</surname><given-names>R.</given-names></name><name><surname>Larrosa</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Gut Microbiota Modification: Another Piece in the Puzzle of the Benefits of Physical Exercise in Health</article-title>? <source/>Front. Physiol.
<volume>7</volume> (<issue>51</issue>).  <pub-id pub-id-type="doi">10.3389/fphys.2016.00051</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Ishigami</surname><given-names>T.</given-names></name><name><surname>Nakashima-Sasaki</surname><given-names>R.</given-names></name><name><surname>Kino</surname><given-names>T.</given-names></name><name><surname>Doi</surname><given-names>H.</given-names></name><name><surname>Minegishi</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Commensal Microbe-specific Activation of B2 Cell Subsets Contributes to Atherosclerosis Development Independently of Lipid Metabolism</article-title>. <source/>EBioMedicine
<volume>13</volume>, <fpage>237</fpage>–<lpage>247</lpage>.  <pub-id pub-id-type="doi">10.1016/j.ebiom.2016.10.030</pub-id>
<pub-id pub-id-type="pmid">27810309</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clarke</surname><given-names>G.</given-names></name><name><surname>Sandhu</surname><given-names>K. V.</given-names></name><name><surname>Griffin</surname><given-names>B. T.</given-names></name><name><surname>Dinan</surname><given-names>T. G.</given-names></name><name><surname>Cryan</surname><given-names>J. F.</given-names></name><name><surname>Hyland</surname><given-names>N. P.</given-names></name></person-group> (<year>2019</year>). <article-title>Gut Reactions: Breaking Down Xenobiotic–Microbiome Interactions</article-title>. <source/>Pharmacol. Rev.
<volume>71</volume>, <fpage>198</fpage>–<lpage>224</lpage>.  <pub-id pub-id-type="doi">10.1124/pr.118.015768</pub-id>
<pub-id pub-id-type="pmid">30890566</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cole</surname><given-names>J. E.</given-names></name><name><surname>Astola</surname><given-names>N.</given-names></name><name><surname>Cribbs</surname><given-names>A. P.</given-names></name><name><surname>Goddard</surname><given-names>M. E.</given-names></name><name><surname>Park</surname><given-names>I.</given-names></name><name><surname>Green</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>112</volume>, <fpage>13033</fpage>–<lpage>13038</lpage>.  <pub-id pub-id-type="doi">10.1073/pnas.1517820112</pub-id>
<pub-id pub-id-type="pmid">26438837</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Costantini</surname><given-names>L.</given-names></name><name><surname>Molinari</surname><given-names>R.</given-names></name><name><surname>Farinon</surname><given-names>B.</given-names></name><name><surname>Merendino</surname><given-names>N.</given-names></name></person-group> (<year>2017</year>). <article-title>Impact of Omega-3 Fatty Acids on the Gut Microbiota</article-title>. <source/>Int. J. Mol. Sci.
<volume>18</volume> (<issue>2645</issue>), <fpage>1</fpage>–<lpage>8</lpage>.  <pub-id pub-id-type="doi">10.3390/ijms18122645</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cotillard</surname><given-names>A.</given-names></name><name><surname>Kennedy</surname><given-names>S. P.</given-names></name><name><surname>Kong</surname><given-names>L. C.</given-names></name><name><surname>Prifti</surname><given-names>E.</given-names></name><name><surname>Pons</surname><given-names>N.</given-names></name><name><surname>Le Chatelier</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Dietary intervention impact on gut microbial gene richness</article-title>. <source/>Nature
<volume>500</volume>, <fpage>585</fpage>–<lpage>588</lpage>.  <pub-id pub-id-type="doi">10.1038/nature12480</pub-id>
<pub-id pub-id-type="pmid">23985875</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Danielsson</surname><given-names>H.</given-names></name><name><surname>Gustafsson</surname><given-names>B.</given-names></name></person-group> (<year>1959</year>). <article-title>On serum-cholesterol levels and neutral fecal sterols in germ-free rats. Bile acids and steroids 59</article-title>. <source/>Arch. Biochem. Biophys.
<volume>83</volume>, <fpage>482</fpage>–<lpage>485</lpage>.  <pub-id pub-id-type="doi">10.1016/0003-9861(59)90056-6</pub-id>
<pub-id pub-id-type="pmid">13813997</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dao</surname><given-names>M. C.</given-names></name><name><surname>Everard</surname><given-names>A.</given-names></name><name><surname>Aron-Wisnewsky</surname><given-names>J.</given-names></name><name><surname>Sokolovska</surname><given-names>N.</given-names></name><name><surname>Prifti</surname><given-names>E.</given-names></name><name><surname>Verger</surname><given-names>E. O.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology</article-title>. <source/>Gut
<volume>65</volume>, <fpage>426</fpage>–<lpage>436</lpage>.  <pub-id pub-id-type="doi">10.1136/gutjnl-2014-308778</pub-id>
<pub-id pub-id-type="pmid">26100928</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dawson</surname><given-names>P. A.</given-names></name><name><surname>Karpen</surname><given-names>S. J.</given-names></name></person-group> (<year>2015</year>). <article-title>Intestinal transport and metabolism of bile acids</article-title>. <source/>J. Lipid Res.
<volume>56</volume>, <fpage>1085</fpage>–<lpage>1099</lpage>.  <pub-id pub-id-type="doi">10.1194/jlr.R054114</pub-id>
<pub-id pub-id-type="pmid">25210150</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Boer</surname><given-names>J. F.</given-names></name><name><surname>Bloks</surname><given-names>V. W.</given-names></name><name><surname>Verkade</surname><given-names>E.</given-names></name><name><surname>Heiner-Fokkema</surname><given-names>M. R.</given-names></name><name><surname>Kuipers</surname><given-names>F.</given-names></name></person-group> (<year>2018</year>). <article-title>New insights in the multiple roles of bile acids and their signaling pathways in metabolic control</article-title>. <source/>Curr. Opin. Lipidol.
<volume>29</volume>, <fpage>194</fpage>–<lpage>202</lpage>.  <pub-id pub-id-type="doi">10.1097/MOL.0000000000000508</pub-id>
<pub-id pub-id-type="pmid">29553998</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Moraes</surname><given-names>A. C. F.</given-names></name><name><surname>Fernandes</surname><given-names>G. R.</given-names></name><name><surname>da Silva</surname><given-names>I. T.</given-names></name><name><surname>Almeida-Pititto</surname><given-names>B.</given-names></name><name><surname>Gomes</surname><given-names>E. P.</given-names></name><name><surname>Pereira</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Enterotype May Drive the Dietary-Associated Cardiometabolic Risk Factors</article-title>. <source/>Front. Cell. Infect. Microbiol.
<volume>7</volume> (<issue>47</issue>).  <pub-id pub-id-type="doi">10.3389/fcimb.2017.00047</pub-id>
</mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deaton</surname><given-names>A. M.</given-names></name><name><surname>Sulem</surname><given-names>P.</given-names></name><name><surname>Nioi</surname><given-names>P.</given-names></name><name><surname>Benonisdottir</surname><given-names>S.</given-names></name><name><surname>Ward</surname><given-names>L. D.</given-names></name><name><surname>Davidsson</surname><given-names>O. B.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>A rare missense variant in NR1H4 associates with lower cholesterol levels</article-title>. <source/>Commun. Biol.
<volume>1</volume> (<issue>47</issue>), <fpage>1</fpage>–<lpage>14</lpage>.  <pub-id pub-id-type="doi">10.1038/s42003-018-0015-9</pub-id>
<pub-id pub-id-type="pmid">29809203</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Demigné</surname><given-names>C.</given-names></name><name><surname>Morand</surname><given-names>C.</given-names></name><name><surname>Levrat</surname><given-names>M. A.</given-names></name><name><surname>Besson</surname><given-names>C.</given-names></name><name><surname>Moundras</surname><given-names>C.</given-names></name><name><surname>Rémésy</surname><given-names>C.</given-names></name></person-group> (<year>1995</year>). <article-title>Effect of propionate on fatty acid and cholesterol synthesis and on acetate metabolism in isolated rat hepatocytes</article-title>. <source/>Br. J. Nutr.
<volume>74</volume>, <fpage>209</fpage>–<lpage>219</lpage>.  <pub-id pub-id-type="doi">10.1079/bjn19950124</pub-id>
<pub-id pub-id-type="pmid">7547838</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>den Besten</surname><given-names>G.</given-names></name><name><surname>Lange</surname><given-names>K.</given-names></name><name><surname>Havinga</surname><given-names>R.</given-names></name><name><surname>van Dijk</surname><given-names>T. H.</given-names></name><name><surname>Gerding</surname><given-names>A.</given-names></name><name><surname>van Eunen</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids</article-title>. <source/>Am. J. Physiol.-Gastrointest. Liver Physiol.
<volume>305</volume>, <fpage>G900</fpage>–<lpage>G910</lpage>.  <pub-id pub-id-type="doi">10.1152/ajpgi.00265.2013</pub-id>
<pub-id pub-id-type="pmid">24136789</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Devlin</surname><given-names>A. S.</given-names></name><name><surname>Fischbach</surname><given-names>M. A.</given-names></name></person-group> (<year>2015</year>). <article-title>A biosynthetic pathway for a prominent class of microbiota-derived bile acids</article-title>. <source/>Nat. Chem. Biol.
<volume>11</volume>, <fpage>685</fpage>–<lpage>690</lpage>.  <pub-id pub-id-type="doi">10.1038/nchembio.1864</pub-id>
<pub-id pub-id-type="pmid">26192599</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Doherty</surname><given-names>M. K.</given-names></name><name><surname>Ding</surname><given-names>T.</given-names></name><name><surname>Koumpouras</surname><given-names>C.</given-names></name><name><surname>Telesco</surname><given-names>S. E.</given-names></name><name><surname>Monast</surname><given-names>C.</given-names></name><name><surname>Das</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn’s Disease Patients</article-title>. <source/>mBio
<volume>9</volume>, <fpage>e02120</fpage>–<lpage>e02117</lpage>.  <pub-id pub-id-type="doi">10.1128/mBio.02120-17</pub-id>
</mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Du</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Su</surname><given-names>C.</given-names></name><name><surname>Xi</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Jiang</surname><given-names>Z.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Butyrate protects against high-fat diet-induced atherosclerosis via up-regulating ABCA1 expression in apolipoprotein E-deficiency mice</article-title>. <source/>Br. J. Pharmacol. <volume>177</volume>, <fpage>1754</fpage>–<lpage>1772</lpage>.  <pub-id pub-id-type="doi">10.1111/bph.14933</pub-id>
</mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eggink</surname><given-names>H. M.</given-names></name><name><surname>van Nierop</surname><given-names>F. S.</given-names></name><name><surname>Schooneman</surname><given-names>M. G.</given-names></name><name><surname>Boelen</surname><given-names>A.</given-names></name><name><surname>Kalsbeek</surname><given-names>A.</given-names></name><name><surname>Koehorst</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Transhepatic bile acid kinetics in pigs and humans</article-title>. <source/>Clin. Nutr.
<volume>37</volume>, <fpage>1406</fpage>–<lpage>1414</lpage>.  <pub-id pub-id-type="doi">10.1016/j.clnu.2017.06.015</pub-id>
<pub-id pub-id-type="pmid">28669667</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ejtahed</surname><given-names>H.-S.</given-names></name><name><surname>Angorani</surname><given-names>P.</given-names></name><name><surname>Soroush</surname><given-names>A.-R.</given-names></name><name><surname>Siadat</surname><given-names>S.-D.</given-names></name><name><surname>Shirzad</surname><given-names>N.</given-names></name><name><surname>Larijani</surname><given-names>S. H.-R.</given-names></name></person-group> (<year>1969</year>). <article-title>Our Little Friends with Big Roles: Alterations of the Gut Microbiota in Thyroid Disorders</article-title>. <source/>Endocr. Metab. Immune Disord. - Drug Targets.  <pub-id pub-id-type="doi">10.2174/1871530319666190930110605</pub-id>
</mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fändriks</surname><given-names>L.</given-names></name></person-group> (<year>2017</year>). <article-title>Roles of the gut in the metabolic syndrome: an overview</article-title>. <source/>J. Intern. Med.
<volume>281</volume>, <fpage>319</fpage>–<lpage>336</lpage>.  <pub-id pub-id-type="doi">10.1111/joim.12584</pub-id>
<pub-id pub-id-type="pmid">27991713</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ference</surname><given-names>B. A.</given-names></name><name><surname>Ginsberg</surname><given-names>H. N.</given-names></name><name><surname>Graham</surname><given-names>I.</given-names></name><name><surname>Ray</surname><given-names>K. K.</given-names></name><name><surname>Packard</surname><given-names>C. J.</given-names></name><name><surname>Bruckert</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel</article-title>. <source/>Eur. Heart J.
<volume>38</volume>, <fpage>2459</fpage>–<lpage>2472</lpage>.  <pub-id pub-id-type="doi">10.1093/eurheartj/ehx144</pub-id>
<pub-id pub-id-type="pmid">28444290</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>D. M.</given-names></name><name><surname>Rahman</surname><given-names>A. H.</given-names></name><name><surname>Fernandez</surname><given-names>N. F.</given-names></name><name><surname>Chudnovskiy</surname><given-names>A.</given-names></name><name><surname>Amir</surname><given-names>E. D.</given-names></name><name><surname>Amadori</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Single-cell immune landscape of human atherosclerotic plaques</article-title>. <source/>Nat. Med.
<volume>25</volume>, <fpage>1576</fpage>–<lpage>1588</lpage>.  <pub-id pub-id-type="doi">10.1038/s41591-019-0590-4</pub-id>
<pub-id pub-id-type="pmid">31591603</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>M.-L.</given-names></name></person-group> (<year>2001</year>). <article-title>Soluble fiber and nondigestible carbohydrate effects on plasma lipids and cardiovascular risk</article-title>. <source/>Curr. Opin. Lipidol.
<volume>12</volume>, <fpage>35</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1097/00041433-200102000-00007</pub-id>
<pub-id pub-id-type="pmid">11176201</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>D. F.</given-names></name><name><surname>Fiamoncini</surname><given-names>J.</given-names></name><name><surname>Prist</surname><given-names>I. H.</given-names></name><name><surname>Ariga</surname><given-names>S. K.</given-names></name><name><surname>de Souza</surname><given-names>H. P.</given-names></name><name><surname>de Lima</surname><given-names>T. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Novel role of TLR4 in NAFLD development: Modulation of metabolic enzymes expression</article-title>. <source/>Biochim. Biophys. Acta
<volume>1851</volume>, <fpage>1353</fpage>–<lpage>1359</lpage>.  <pub-id pub-id-type="doi">10.1016/j.bbalip.2015.07.002</pub-id>
<pub-id pub-id-type="pmid">26172853</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Filippis</surname><given-names>F. D.</given-names></name><name><surname>Pellegrini</surname><given-names>N.</given-names></name><name><surname>Vannini</surname><given-names>L.</given-names></name><name><surname>Jeffery</surname><given-names>I. B.</given-names></name><name><surname>Storia</surname><given-names>A. L.</given-names></name><name><surname>Laghi</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome</article-title>. <source/>Gut
<volume>65</volume>, <fpage>1812</fpage>–<lpage>1821</lpage>.  <pub-id pub-id-type="doi">10.1136/gutjnl-2015-309957</pub-id>
<pub-id pub-id-type="pmid">26416813</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Foster</surname><given-names>K. R.</given-names></name><name><surname>Schluter</surname><given-names>J.</given-names></name><name><surname>Coyte</surname><given-names>K. Z.</given-names></name><name><surname>Rakoff-Nahoum</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>The evolution of the host microbiome as an ecosystem on a leash</article-title>. <source/>Nature
<volume>548</volume>, <fpage>43</fpage>–<lpage>51</lpage>.  <pub-id pub-id-type="doi">10.1038/nature23292</pub-id>
<pub-id pub-id-type="pmid">28770836</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fu</surname><given-names>J.</given-names></name><name><surname>Bonder</surname><given-names>M. J.</given-names></name><name><surname>Cenit</surname><given-names>M. C.</given-names></name><name><surname>Tigchelaar</surname><given-names>E. F.</given-names></name><name><surname>Maatman</surname><given-names>A.</given-names></name><name><surname>Dekens</surname><given-names>J. A. M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids</article-title>. <source/>Circ. Res.
<volume>117</volume>, <fpage>817</fpage>–<lpage>824</lpage>.  <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.306807</pub-id>
<pub-id pub-id-type="pmid">26358192</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fushimi</surname><given-names>T.</given-names></name><name><surname>Suruga</surname><given-names>K.</given-names></name><name><surname>Oshima</surname><given-names>Y.</given-names></name><name><surname>Fukiharu</surname><given-names>M.</given-names></name><name><surname>Tsukamoto</surname><given-names>Y.</given-names></name><name><surname>Goda</surname><given-names>T.</given-names></name></person-group> (<year>2006</year>). <article-title>Dietary acetic acid reduces serum cholesterol and triacylglycerols in rats fed a cholesterol-rich diet</article-title>. <source/>Br. J. Nutr.
<volume>95</volume>, <fpage>916</fpage>–<lpage>924</lpage>.  <pub-id pub-id-type="doi">10.1079/BJN20061740</pub-id>
<pub-id pub-id-type="pmid">16611381</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gérard</surname><given-names>P.</given-names></name><name><surname>Béguet</surname><given-names>F.</given-names></name><name><surname>Lepercq</surname><given-names>P.</given-names></name><name><surname>Rigottier-Gois</surname><given-names>L.</given-names></name><name><surname>Rochet</surname><given-names>V.</given-names></name><name><surname>Andrieux</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Gnotobiotic rats harboring human intestinal microbiota as a model for studying cholesterol-to-coprostanol conversion</article-title>. <source/>FEMS Microbiol. Ecol.
<volume>47</volume>, <fpage>337</fpage>–<lpage>343</lpage>.  <pub-id pub-id-type="doi">10.1016/S0168-6496(03)00285-X</pub-id>
<pub-id pub-id-type="pmid">19712322</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gérard</surname><given-names>P.</given-names></name></person-group> (<year>2013</year>). <article-title>Metabolism of cholesterol and bile acids by the gut microbiota</article-title>. <source/>Pathog. Basel Switz.
<volume>3</volume>, <fpage>14</fpage>–<lpage>24</lpage>.  <pub-id pub-id-type="doi">10.3390/pathogens3010014</pub-id>
</mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gomes Torres</surname><given-names>A. C. M. B.</given-names></name><name><surname>Leite</surname><given-names>N.</given-names></name><name><surname>Tureck</surname><given-names>L. V.</given-names></name><name><surname>de Souza</surname><given-names>R. L. R.</given-names></name><name><surname>Titski</surname><given-names>A. C. K.</given-names></name><name><surname>Milano-Gai</surname><given-names>G. E.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Association between Toll-like receptors (TLR) and NOD-like receptor (NLR) polymorphisms and lipid and glucose metabolism</article-title>. <source/>Gene
<volume>685</volume>, <fpage>211</fpage>–<lpage>221</lpage>.  <pub-id pub-id-type="doi">10.1016/j.gene.2018.11.065</pub-id>
<pub-id pub-id-type="pmid">30481552</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goode</surname><given-names>E. L.</given-names></name><name><surname>Cherny</surname><given-names>S. S.</given-names></name><name><surname>Christian</surname><given-names>J. C.</given-names></name><name><surname>Jarvik</surname><given-names>G. P.</given-names></name><name><surname>de Andrade</surname><given-names>M.</given-names></name></person-group> (<year>2007</year>). <article-title>Heritability of longitudinal measures of body mass index and lipid and lipoprotein levels in aging twins</article-title>. <source/>Twin Res. Hum. Genet. Off. J. Int. Soc Twin Stud.
<volume>10</volume>, <fpage>703</fpage>–<lpage>711</lpage>.  <pub-id pub-id-type="doi">10.1375/twin.10.5.703</pub-id>
</mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Griffin</surname><given-names>J. D.</given-names></name><name><surname>Lichtenstein</surname><given-names>A. H.</given-names></name></person-group> (<year>2013</year>). <article-title>Dietary Cholesterol and Plasma Lipoprotein Profiles: Randomized-Controlled Trials</article-title>. <source/>Curr. Nutr. Rep.
<volume>2</volume>, <fpage>274</fpage>–<lpage>282</lpage>.  <pub-id pub-id-type="doi">10.1007/s13668-013-0064-0</pub-id>
<pub-id pub-id-type="pmid">24466502</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Groen</surname><given-names>A. K.</given-names></name><name><surname>Bloks</surname><given-names>V. W.</given-names></name><name><surname>Verkade</surname><given-names>H.</given-names></name><name><surname>Kuipers</surname><given-names>F.</given-names></name></person-group> (<year>2014</year>). <article-title>Cross-talk between liver and intestine in control of cholesterol and energy homeostasis</article-title>. <source/>Mol. Aspects Med.
<volume>37</volume>, <fpage>77</fpage>–<lpage>88</lpage>.  <pub-id pub-id-type="doi">10.1016/j.mam.2014.02.001</pub-id>
<pub-id pub-id-type="pmid">24560594</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhong</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment</article-title>. <source/>Nat. Commun.
<volume>8</volume>, <fpage>1</fpage>–<lpage>12</lpage>.  <pub-id pub-id-type="doi">10.1038/s41467-017-01682-2</pub-id>
<pub-id pub-id-type="pmid">28232747</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Jain</surname><given-names>R.</given-names></name><name><surname>Shi</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Circadian control of bile acid synthesis by a KLF15-Fgf15 axis</article-title>. <source/>Nat. Commun.
<volume>6</volume>, <fpage>7231</fpage>.  <pub-id pub-id-type="doi">10.1038/ncomms8231</pub-id>
<pub-id pub-id-type="pmid">26040986</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harris</surname><given-names>H. W.</given-names></name><name><surname>Gosnell</surname><given-names>J. E.</given-names></name><name><surname>Kumwenda</surname><given-names>Z. L.</given-names></name></person-group> (<year>2000</year>). <article-title>The lipemia of sepsis: triglyceride-rich lipoproteins as agents of innate immunity</article-title>. <source/>J. Endotoxin Res.
<volume>6</volume>, <fpage>421</fpage>–<lpage>430</lpage>.<pub-id pub-id-type="pmid">11521066</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>N.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Feng</surname><given-names>J.</given-names></name><name><surname>Jia</surname><given-names>W.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Gut Microbiota Modulation Attenuated the Hypolipidemic Effect of Simvastatin in High-Fat/Cholesterol-Diet Fed Mice</article-title>. <source/>J. Proteome Res.
<volume>16</volume>, <fpage>1900</fpage>–<lpage>1910</lpage>.  <pub-id pub-id-type="doi">10.1021/acs.jproteome.6b00984</pub-id>
<pub-id pub-id-type="pmid">28378586</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hennessy</surname><given-names>E.</given-names></name><name><surname>Adams</surname><given-names>C.</given-names></name><name><surname>Reen</surname><given-names>F. J.</given-names></name><name><surname>O’Gara</surname><given-names>F.</given-names></name></person-group> (<year>2016</year>). <article-title>Is There Potential for Repurposing Statins as Novel Antimicrobials</article-title>? <source/>Antimicrob. Agents Chemother.
<volume>60</volume>, <fpage>5111</fpage>–<lpage>5121</lpage>.  <pub-id pub-id-type="doi">10.1128/AAC.00192-16</pub-id>
<pub-id pub-id-type="pmid">27324773</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Higashimori</surname><given-names>M.</given-names></name><name><surname>Tatro</surname><given-names>J. B.</given-names></name><name><surname>Moore</surname><given-names>K. J.</given-names></name><name><surname>Mendelsohn</surname><given-names>M. E.</given-names></name><name><surname>Galper</surname><given-names>J. B.</given-names></name><name><surname>Beasley</surname><given-names>D.</given-names></name></person-group> (<year>2011</year>). <article-title>Role of toll-like receptor 4 in intimal foam cell accumulation in apolipoprotein E-deficient mice</article-title>. <source/>Arterioscler. Thromb. Vasc. Biol.
<volume>31</volume>, <fpage>50</fpage>–<lpage>57</lpage>.  <pub-id pub-id-type="doi">10.1161/ATVBAHA.110.210971</pub-id>
<pub-id pub-id-type="pmid">20966403</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>T. J.</given-names></name><name><surname>Theusch</surname><given-names>E.</given-names></name><name><surname>Haldar</surname><given-names>T.</given-names></name><name><surname>Ranatunga</surname><given-names>D. K.</given-names></name><name><surname>Jorgenson</surname><given-names>E.</given-names></name><name><surname>Medina</surname><given-names>M. W.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>A large electronic-health-record-based genome-wide study of serum lipids</article-title>. <source/>Nat. Genet.
<volume>50</volume>, <fpage>401</fpage>–<lpage>413</lpage>.  <pub-id pub-id-type="doi">10.1038/s41588-018-0064-5</pub-id>
<pub-id pub-id-type="pmid">29507422</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>A. F.</given-names></name><name><surname>Hagey</surname><given-names>L. R.</given-names></name></person-group> (<year>2014</year>). <article-title>Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades</article-title>. <source/>J. Lipid Res.
<volume>55</volume>, <fpage>1553</fpage>–<lpage>1595</lpage>.  <pub-id pub-id-type="doi">10.1194/jlr.R049437</pub-id>
<pub-id pub-id-type="pmid">24838141</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>A. F.</given-names></name></person-group> (<year>1999</year>). <article-title>Bile Acids: The Good, the Bad, and the Ugly</article-title>. <source/>Physiology
<volume>14</volume>, <fpage>24</fpage>–<lpage>29</lpage>.  <pub-id pub-id-type="doi">10.1152/physiologyonline.1999.14.1.24</pub-id>
</mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Houten</surname><given-names>S. M.</given-names></name><name><surname>Watanabe</surname><given-names>M.</given-names></name><name><surname>Auwerx</surname><given-names>J.</given-names></name></person-group> (<year>2006</year>). <article-title>Endocrine functions of bile acids</article-title>. <source/>EMBO J.
<volume>25</volume>, <fpage>1419</fpage>–<lpage>1425</lpage>.  <pub-id pub-id-type="doi">10.1038/sj.emboj.7601049</pub-id>
<pub-id pub-id-type="pmid">16541101</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoyles</surname><given-names>L.</given-names></name><name><surname>Fernández-Real</surname><given-names>J.-M.</given-names></name><name><surname>Federici</surname><given-names>M.</given-names></name><name><surname>Serino</surname><given-names>M.</given-names></name><name><surname>Abbott</surname><given-names>J.</given-names></name><name><surname>Charpentier</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women</article-title>. <source/>Nat. Med.
<volume>24</volume>, <fpage>1070</fpage>–<lpage>1080</lpage>.  <pub-id pub-id-type="doi">10.1038/s41591-018-0061-3</pub-id>
<pub-id pub-id-type="pmid">29942096</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Fang</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>He</surname><given-names>M.</given-names></name><name><surname>Ke</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Evaluating the contribution of gut microbiome to the variance of porcine serum glucose and lipid concentration</article-title>. <source/>Sci. Rep.
<volume>7</volume>, <fpage>14928</fpage>.  <pub-id pub-id-type="doi">10.1038/s41598-017-15044-x</pub-id>
<pub-id pub-id-type="pmid">29097803</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jakulj</surname><given-names>L.</given-names></name><name><surname>van Dijk</surname><given-names>T. H.</given-names></name><name><surname>de Boer</surname><given-names>J. F.</given-names></name><name><surname>Kootte</surname><given-names>R. S.</given-names></name><name><surname>Schonewille</surname><given-names>M.</given-names></name><name><surname>Paalvast</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Transintestinal Cholesterol Transport Is Active in Mice and Humans and Controls Ezetimibe-Induced Fecal Neutral Sterol Excretion</article-title>. <source/>Cell Metab.
<volume>24</volume>, <fpage>783</fpage>–<lpage>794</lpage>.  <pub-id pub-id-type="doi">10.1016/j.cmet.2016.10.001</pub-id>
<pub-id pub-id-type="pmid">27818259</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>D. J. A.</given-names></name><name><surname>Kendall</surname><given-names>C. W. C.</given-names></name><name><surname>Hamidi</surname><given-names>M.</given-names></name><name><surname>Vidgen</surname><given-names>E.</given-names></name><name><surname>Faulkner</surname><given-names>D.</given-names></name><name><surname>Parker</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>Effect of antibiotics as cholesterol-lowering agents</article-title>. <source/>Metabolism
<volume>54</volume>, <fpage>103</fpage>–<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1016/j.metabol.2004.07.019</pub-id>
<pub-id pub-id-type="pmid">15562388</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>D.</given-names></name><name><surname>Wolever</surname><given-names>T.</given-names></name><name><surname>Rao</surname><given-names>A. V.</given-names></name><name><surname>Hegele</surname><given-names>R. A.</given-names></name><name><surname>Mitchell</surname><given-names>S. J.</given-names></name><name><surname>Ransom</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Effect on Blood Lipids of Very High Intakes of Fiber in Diets Low in Saturated Fat and Cholesterol</article-title>. <source/>N. Engl. J. Med.
<volume>329</volume> (<issue>1</issue>), <fpage>21</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM199307013290104</pub-id>
</mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jönsson</surname><given-names>G.</given-names></name><name><surname>Midtvedt</surname><given-names>A. C.</given-names></name><name><surname>Norman</surname><given-names>A.</given-names></name><name><surname>Midtvedt</surname><given-names>T.</given-names></name></person-group> (<year>1995</year>). <article-title>Intestinal microbial bile acid transformation in healthy infants</article-title>. <source/>J. Pediatr. Gastroenterol. Nutr.
<volume>20</volume>, <fpage>394</fpage>–<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1097/00005176-199505000-00004</pub-id>
<pub-id pub-id-type="pmid">7636681</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Joyce</surname><given-names>S. A.</given-names></name><name><surname>MacSharry</surname><given-names>J.</given-names></name><name><surname>Casey</surname><given-names>P. G.</given-names></name><name><surname>Kinsella</surname><given-names>M.</given-names></name><name><surname>Murphy</surname><given-names>E. F.</given-names></name><name><surname>Shanahan</surname><given-names>F.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>111</volume>, <fpage>7421</fpage>–<lpage>7426</lpage>.  <pub-id pub-id-type="doi">10.1073/pnas.1323599111</pub-id>
<pub-id pub-id-type="pmid">24799697</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kakiyama</surname><given-names>G.</given-names></name><name><surname>Pandak</surname><given-names>W. M.</given-names></name><name><surname>Gillevet</surname><given-names>P. M.</given-names></name><name><surname>Hylemon</surname><given-names>P. B.</given-names></name><name><surname>Heuman</surname><given-names>D. M.</given-names></name><name><surname>Daita</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Modulation of the fecal bile acid profile by gut microbiota in cirrhosis</article-title>. <source/>J. Hepatol.
<volume>58</volume>, <fpage>949</fpage>–<lpage>955</lpage>.  <pub-id pub-id-type="doi">10.1016/j.jhep.2013.01.003</pub-id>
<pub-id pub-id-type="pmid">23333527</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kang</surname><given-names>D. J.</given-names></name><name><surname>Hylemon</surname><given-names>P. B.</given-names></name><name><surname>Gillevet</surname><given-names>P. M.</given-names></name><name><surname>Sartor</surname><given-names>R. B.</given-names></name><name><surname>Betrapally</surname><given-names>N. S.</given-names></name><name><surname>Kakiyama</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Gut microbial composition can differentially regulate bile acid synthesis in humanized mice</article-title>. <source/>Hepatol. Commun.
<volume>1</volume>, <fpage>61</fpage>–<lpage>70</lpage>.  <pub-id pub-id-type="doi">10.1002/hep4.1020</pub-id>
<pub-id pub-id-type="pmid">29404434</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaptoge</surname><given-names>S.</given-names></name><name><surname>Pennells</surname><given-names>L.</given-names></name><name><surname>De Bacquer</surname><given-names>D.</given-names></name><name><surname>Cooney</surname><given-names>M. T.</given-names></name><name><surname>Kavousi</surname><given-names>M.</given-names></name><name><surname>Stevens</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions</article-title>. <source/>Lancet Glob. Health
<volume>7</volume>, <fpage>e1332</fpage>–<lpage>e1345</lpage>.  <pub-id pub-id-type="doi">10.1016/S2214-109X(19)30318-3</pub-id>
<pub-id pub-id-type="pmid">31488387</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karlsson</surname><given-names>F. H.</given-names></name><name><surname>Tremaroli</surname><given-names>V.</given-names></name><name><surname>Nookaew</surname><given-names>I.</given-names></name><name><surname>Bergström</surname><given-names>G.</given-names></name><name><surname>Behre</surname><given-names>C. J.</given-names></name><name><surname>Fagerberg</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Gut metagenome in European women with normal, impaired and diabetic glucose control</article-title>. <source/>Nature
<volume>498</volume>, <fpage>99</fpage>–<lpage>103</lpage>.  <pub-id pub-id-type="doi">10.1038/nature12198</pub-id>
<pub-id pub-id-type="pmid">23719380</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kasahara</surname><given-names>K.</given-names></name><name><surname>Tanoue</surname><given-names>T.</given-names></name><name><surname>Yamashita</surname><given-names>T.</given-names></name><name><surname>Yodoi</surname><given-names>K.</given-names></name><name><surname>Matsumoto</surname><given-names>T.</given-names></name><name><surname>Emoto</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Commensal bacteria at the crossroad between cholesterol homeostasis and chronic inflammation in atherosclerosis</article-title>. <source/>J. Lipid Res.
<volume>58</volume>, <fpage>519</fpage>–<lpage>528</lpage>.  <pub-id pub-id-type="doi">10.1194/jlr.M072165</pub-id>
<pub-id pub-id-type="pmid">28130274</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khera</surname><given-names>A. V.</given-names></name><name><surname>Won</surname><given-names>H.-H.</given-names></name><name><surname>Peloso</surname><given-names>G. M.</given-names></name><name><surname>Lawson</surname><given-names>K. S.</given-names></name><name><surname>Bartz</surname><given-names>T. M.</given-names></name><name><surname>Deng</surname><given-names>X.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia</article-title>. <source/>J. Am. Coll. Cardiol.
<volume>67</volume>, <fpage>2578</fpage>–<lpage>2589</lpage>.  <pub-id pub-id-type="doi">10.1016/j.jacc.2016.03.520</pub-id>
<pub-id pub-id-type="pmid">27050191</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khovidhunkit</surname><given-names>W.</given-names></name><name><surname>Kim</surname><given-names>M.-S.</given-names></name><name><surname>Memon</surname><given-names>R. A.</given-names></name><name><surname>Shigenaga</surname><given-names>J. K.</given-names></name><name><surname>Moser</surname><given-names>A. H.</given-names></name><name><surname>Feingold</surname><given-names>K. R.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host</article-title>. <source/>J. Lipid Res.
<volume>45</volume>, <fpage>1169</fpage>–<lpage>1196</lpage>.  <pub-id pub-id-type="doi">10.1194/jlr.R300019-JLR200</pub-id>
<pub-id pub-id-type="pmid">15102878</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kilpeläinen</surname><given-names>T. O.</given-names></name><name><surname>Bentley</surname><given-names>A. R.</given-names></name><name><surname>Noordam</surname><given-names>R.</given-names></name><name><surname>Sung</surname><given-names>Y. J.</given-names></name><name><surname>Schwander</surname><given-names>K.</given-names></name><name><surname>Winkler</surname><given-names>T. W.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Multi-ancestry study of blood lipid levels identifies four loci interacting with physical activity</article-title>. <source/>Nat. Commun.
<volume>10</volume>, <fpage>376</fpage>.  <pub-id pub-id-type="doi">10.1038/s41467-018-08008-w</pub-id>
<pub-id pub-id-type="pmid">30670697</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kiouptsi</surname><given-names>K.</given-names></name><name><surname>Jäckel</surname><given-names>S.</given-names></name><name><surname>Pontarollo</surname><given-names>G.</given-names></name><name><surname>Grill</surname><given-names>A.</given-names></name><name><surname>Kuijpers</surname><given-names>M. J. E.</given-names></name><name><surname>Wilms</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>The Microbiota Promotes Arterial Thrombosis in Low-Density Lipoprotein Receptor-Deficient Mice</article-title>. <source/>mBio
<volume>10</volume>, <fpage>1</fpage>–<lpage>16</lpage>.  <pub-id pub-id-type="doi">10.1128/mBio.02298-19</pub-id>
</mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ko</surname><given-names>H. H. T.</given-names></name><name><surname>Lareu</surname><given-names>R. R.</given-names></name><name><surname>Dix</surname><given-names>B. R.</given-names></name><name><surname>Hughes</surname><given-names>J. D.</given-names></name></person-group> (<year>2017</year>). <article-title>Statins: antimicrobial resistance breakers or makers</article-title>? <source/>PeerJ
<volume>5</volume>, <elocation-id>e3952</elocation-id>.  <pub-id pub-id-type="doi">10.7717/peerj.3952</pub-id>
<pub-id pub-id-type="pmid">29085751</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koeth</surname><given-names>R. A.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Levison</surname><given-names>B. S.</given-names></name><name><surname>Buffa</surname><given-names>J. A.</given-names></name><name><surname>Org</surname><given-names>E.</given-names></name><name><surname>Sheehy</surname><given-names>B. T.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis</article-title>. <source/>Nat. Med.
<volume>19</volume>, <fpage>576</fpage>–<lpage>585</lpage>.  <pub-id pub-id-type="doi">10.1038/nm.3145</pub-id>
<pub-id pub-id-type="pmid">23563705</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koppel</surname><given-names>N.</given-names></name><name><surname>Maini Rekdal</surname><given-names>V.</given-names></name><name><surname>Balskus</surname><given-names>E. P.</given-names></name></person-group> (<year>2017</year>). <article-title>Chemical transformation of xenobiotics by the human gut microbiota</article-title>. <source/>Science
<volume>356</volume>, <fpage>1</fpage>–<lpage>11</lpage>.  <pub-id pub-id-type="doi">10.1126/science.aag2770</pub-id>
</mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koren</surname><given-names>O.</given-names></name><name><surname>Spor</surname><given-names>A.</given-names></name><name><surname>Felin</surname><given-names>J.</given-names></name><name><surname>Fåk</surname><given-names>F.</given-names></name><name><surname>Stombaugh</surname><given-names>J.</given-names></name><name><surname>Tremaroli</surname><given-names>V.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Human oral, gut, and plaque microbiota in patients with atherosclerosis</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>108</volume> (<issue>Suppl 1</issue>), <fpage>4592</fpage>–<lpage>4598</lpage>.  <pub-id pub-id-type="doi">10.1073/pnas.1011383107</pub-id>
<pub-id pub-id-type="pmid">20937873</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kvit</surname><given-names>K. B.</given-names></name><name><surname>Kharchenko</surname><given-names>N. V.</given-names></name><name><surname>Kharchenko</surname><given-names>V. V.</given-names></name><name><surname>Chornenka</surname><given-names>O. I.</given-names></name><name><surname>Chornovus</surname><given-names>R. I.</given-names></name><name><surname>Dorofeeva</surname><given-names>U. S.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>The role of small intestinal bacterial overgrowth in the pathogenesis of hyperlipidemia</article-title>. <source/>Wiadomosci Lek. Wars. Pol. 1960
<volume>72</volume>, <fpage>645</fpage>–<lpage>649</lpage>.</mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Le Chatelier</surname><given-names>E.</given-names></name><name><surname>Nielsen</surname><given-names>T.</given-names></name><name><surname>Qin</surname><given-names>J.</given-names></name><name><surname>Prifti</surname><given-names>E.</given-names></name><name><surname>Hildebrand</surname><given-names>F.</given-names></name><name><surname>Falony</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Richness of human gut microbiome correlates with metabolic markers</article-title>. <source/>Nature
<volume>500</volume>, <fpage>541</fpage>–<lpage>546</lpage>.  <pub-id pub-id-type="doi">10.1038/nature12506</pub-id>
<pub-id pub-id-type="pmid">23985870</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Le Roy</surname><given-names>T.</given-names></name><name><surname>Lécuyer</surname><given-names>E.</given-names></name><name><surname>Chassaing</surname><given-names>B.</given-names></name><name><surname>Rhimi</surname><given-names>M.</given-names></name><name><surname>Lhomme</surname><given-names>M.</given-names></name><name><surname>Boudebbouze</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>The intestinal microbiota regulates host cholesterol homeostasis</article-title>. <source/>BMC Biol.
<volume>17</volume>, <fpage>94</fpage>.  <pub-id pub-id-type="doi">10.1186/s12915-019-0715-8</pub-id>
<pub-id pub-id-type="pmid">31775890</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lefebvre</surname><given-names>P.</given-names></name><name><surname>Cariou</surname><given-names>B.</given-names></name><name><surname>Lien</surname><given-names>F.</given-names></name><name><surname>Kuipers</surname><given-names>F.</given-names></name><name><surname>Staels</surname><given-names>B.</given-names></name></person-group> (<year>2009</year>). <article-title>Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation</article-title>. <source/>Physiol. Rev.
<volume>89</volume>, <fpage>147</fpage>–<lpage>191</lpage>.  <pub-id pub-id-type="doi">10.1152/physrev.00010.2008</pub-id>
<pub-id pub-id-type="pmid">19126757</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leon</surname><given-names>A. S.</given-names></name><name><surname>Sanchez</surname><given-names>O. A.</given-names></name></person-group> (<year>2001</year>). <article-title>Response of blood lipids to exercise training alone or combined with dietary intervention</article-title>. <source/>Med. Sci. Sports Exerc.
<volume>33</volume>, <fpage>S502</fpage>–<lpage>515</lpage>; discussion S528-529. <pub-id pub-id-type="doi">10.1097/00005768-200106001-00021</pub-id>
<pub-id pub-id-type="pmid">11427777</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Buhman</surname><given-names>K. K.</given-names></name><name><surname>Hartman</surname><given-names>P. A.</given-names></name><name><surname>Beitz</surname><given-names>D. C.</given-names></name></person-group> (<year>1995</year>). <article-title>Hypocholesterolemic effect of Eubacterium coprostanoligenes ATCC 51222 in rabbits</article-title>. <source/>Lett. Appl. Microbiol.
<volume>20</volume>, <fpage>137</fpage>–<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1111/j.1472-765X.1995.tb00410.x</pub-id>
<pub-id pub-id-type="pmid">7766068</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Batt</surname><given-names>S. M.</given-names></name><name><surname>Wannemuehler</surname><given-names>M.</given-names></name><name><surname>Dispirito</surname><given-names>A.</given-names></name><name><surname>Beitz</surname><given-names>D. C.</given-names></name></person-group> (<year>1998</year>). <article-title>Effect of feeding of a cholesterol-reducing bacterium, Eubacterium coprostanoligenes, to germ-free mice</article-title>. <source/>Lab. Anim. Sci.
<volume>48</volume>, <fpage>253</fpage>–<lpage>255</lpage>.<pub-id pub-id-type="pmid">10090024</pub-id></mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>X. S.</given-names></name><name><surname>Obeid</surname><given-names>S.</given-names></name><name><surname>Klingenberg</surname><given-names>R.</given-names></name><name><surname>Gencer</surname><given-names>B.</given-names></name><name><surname>Mach</surname><given-names>F.</given-names></name><name><surname>Räber</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors</article-title>. <source/>Eur. Heart J.
<volume>38</volume>, <fpage>814</fpage>–<lpage>824</lpage>.  <pub-id pub-id-type="doi">10.1093/eurheartj/ehw582</pub-id>
<pub-id pub-id-type="pmid">28077467</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liang</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Qi</surname><given-names>F.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Duan</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>The proatherosclerotic function of indoleamine 2, 3-dioxygenase 1 in the developmental stage of atherosclerosis</article-title>. <source/>Signal Transduction Targeting Ther.
<volume>4</volume>, <fpage>23</fpage>.  <pub-id pub-id-type="doi">10.1038/s41392-019-0058-5</pub-id>
</mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lim</surname><given-names>M. Y.</given-names></name><name><surname>You</surname><given-names>H. J.</given-names></name><name><surname>Yoon</surname><given-names>H. S.</given-names></name><name><surname>Kwon</surname><given-names>B.</given-names></name><name><surname>Lee</surname><given-names>J. Y.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>The effect of heritability and host genetics on the gut microbiota and metabolic syndrome</article-title>. <source/>Gut
<volume>66</volume>, <fpage>1031</fpage>–<lpage>1038</lpage>.  <pub-id pub-id-type="doi">10.1136/gutjnl-2015-311326</pub-id>
<pub-id pub-id-type="pmid">27053630</pub-id></mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lindskog Jonsson</surname><given-names>A.</given-names></name><name><surname>Caesar</surname><given-names>R.</given-names></name><name><surname>Akrami</surname><given-names>R.</given-names></name><name><surname>Reinhardt</surname><given-names>C.</given-names></name><name><surname>Fåk Hållenius</surname><given-names>F.</given-names></name><name><surname>Borén</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Impact of Gut Microbiota and Diet on the Development of Atherosclerosis in Apoe–/– Mice</article-title>. <source/>Arterioscler. Thromb. Vasc. Biol.
<volume>38</volume>, <fpage>2318</fpage>–<lpage>2326</lpage>.  <pub-id pub-id-type="doi">10.1161/ATVBAHA.118.311233</pub-id>
<pub-id pub-id-type="pmid">29903735</pub-id></mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>D. J.</given-names></name><name><surname>Peloso</surname><given-names>G. M.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Butterworth</surname><given-names>A. S.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Mahajan</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Exome-wide association study of plasma lipids in &gt;300,000 individuals</article-title>. <source/>Nat. Genet.
<volume>49</volume>, <fpage>1758</fpage>–<lpage>1766</lpage>.  <pub-id pub-id-type="doi">10.1038/ng.3977</pub-id>
<pub-id pub-id-type="pmid">29083408</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lv</surname><given-names>L.-J.</given-names></name><name><surname>Li</surname><given-names>S.-H.</given-names></name><name><surname>Li</surname><given-names>S.-C.</given-names></name><name><surname>Zhong</surname><given-names>Z.-C.</given-names></name><name><surname>Duan</surname><given-names>H.-L.</given-names></name><name><surname>Tian</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Early-Onset Preeclampsia Is Associated With Gut Microbial Alterations in Antepartum and Postpartum Women</article-title>. <source/>Front. Cell. Infect. Microbiol.
<volume>9</volume>, <elocation-id>224</elocation-id>.  <pub-id pub-id-type="doi">10.3389/fcimb.2019.00224</pub-id>
<pub-id pub-id-type="pmid">31297341</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lynch</surname><given-names>S. V.</given-names></name><name><surname>Pedersen</surname><given-names>O.</given-names></name></person-group> (<year>2016</year>). <article-title>The Human Intestinal Microbiome in Health and Disease</article-title>. <source/>N. Engl. J. Med.
<volume>375</volume>, <fpage>2369</fpage>–<lpage>2379</lpage>.  <pub-id pub-id-type="doi">10.1056/NEJMra1600266</pub-id>
<pub-id pub-id-type="pmid">27974040</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Manor</surname><given-names>O.</given-names></name><name><surname>Zubair</surname><given-names>N.</given-names></name><name><surname>Conomos</surname><given-names>M. P.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Rohwer</surname><given-names>J. E.</given-names></name><name><surname>Krafft</surname><given-names>C. E.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>A Multi-omic Association Study of Trimethylamine N-Oxide</article-title>. <source/>Cell Rep.
<volume>24</volume>, <fpage>935</fpage>–<lpage>946</lpage>.  <pub-id pub-id-type="doi">10.1016/j.celrep.2018.06.096</pub-id>
<pub-id pub-id-type="pmid">30044989</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martínez</surname><given-names>I.</given-names></name><name><surname>Perdicaro</surname><given-names>D. J.</given-names></name><name><surname>Brown</surname><given-names>A. W.</given-names></name><name><surname>Hammons</surname><given-names>S.</given-names></name><name><surname>Carden</surname><given-names>T. J.</given-names></name><name><surname>Carr</surname><given-names>T. P.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Diet-induced alterations of host cholesterol metabolism are likely to affect the gut microbiota composition in hamsters</article-title>. <source/>Appl. Environ. Microbiol.
<volume>79</volume>, <fpage>516</fpage>–<lpage>524</lpage>.  <pub-id pub-id-type="doi">10.1128/AEM.03046-12</pub-id>
<pub-id pub-id-type="pmid">23124234</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maslowski</surname><given-names>K. M.</given-names></name><name><surname>Vieira</surname><given-names>A. T.</given-names></name><name><surname>Ng</surname><given-names>A.</given-names></name><name><surname>Kranich</surname><given-names>J.</given-names></name><name><surname>Sierro</surname><given-names>F.</given-names></name><name><surname>Yu</surname><given-names>Di</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43</article-title>. <source/>Nature
<volume>461</volume>, <fpage>1282</fpage>–<lpage>1286</lpage>.  <pub-id pub-id-type="doi">10.1038/nature08530</pub-id>
<pub-id pub-id-type="pmid">19865172</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matthan</surname><given-names>N. R.</given-names></name><name><surname>Pencina</surname><given-names>M.</given-names></name><name><surname>LaRocque</surname><given-names>J. M.</given-names></name><name><surname>Jacques</surname><given-names>P. F.</given-names></name><name><surname>D’Agostino</surname><given-names>R. B.</given-names></name><name><surname>Schaefer</surname><given-names>E. J.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Alterations in cholesterol absorption/synthesis markers characterize Framingham offspring study participants with CHD</article-title>. <source/>J. Lipid Res.
<volume>50</volume>, <fpage>1927</fpage>–<lpage>1935</lpage>.  <pub-id pub-id-type="doi">10.1194/jlr.P900039-JLR200</pub-id>
<pub-id pub-id-type="pmid">19436064</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Medina</surname><given-names>D. A.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Thomson</surname><given-names>P.</given-names></name><name><surname>Artacho</surname><given-names>A.</given-names></name><name><surname>Pérez-Brocal</surname><given-names>V.</given-names></name><name><surname>Moya</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>Cross-Regional View of Functional and Taxonomic Microbiota Composition in Obesity and Post-obesity Treatment Shows Country Specific Microbial Contribution</article-title>. <source/>Front. Microbiol.
<volume>10</volume>, <elocation-id>2346</elocation-id>.  <pub-id pub-id-type="doi">10.3389/fmicb.2019.02346</pub-id>
<pub-id pub-id-type="pmid">31681211</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mente</surname><given-names>A.</given-names></name><name><surname>Dehghan</surname><given-names>M.</given-names></name><name><surname>Rangarajan</surname><given-names>S.</given-names></name><name><surname>McQueen</surname><given-names>M.</given-names></name><name><surname>Dagenais</surname><given-names>G.</given-names></name><name><surname>Wielgosz</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study</article-title>. <source/>Lancet Diabetes Endocrinol.
<volume>5</volume>, <fpage>774</fpage>–<lpage>787</lpage>.  <pub-id pub-id-type="doi">10.1016/S2213-8587(17)30283-8</pub-id>
<pub-id pub-id-type="pmid">28864143</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Michelsen</surname><given-names>K. S.</given-names></name><name><surname>Wong</surname><given-names>M. H.</given-names></name><name><surname>Shah</surname><given-names>P. K.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Yano</surname><given-names>J.</given-names></name><name><surname>Doherty</surname><given-names>T. M.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E</article-title>. <source/>Proc. Natl. Acad. Sci. U. S. A.
<volume>101</volume>, <fpage>10679</fpage>–<lpage>10684</lpage>.  <pub-id pub-id-type="doi">10.1073/pnas.0403249101</pub-id>
<pub-id pub-id-type="pmid">15249654</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Midtvedt</surname><given-names>T.</given-names></name><name><surname>Lingaas</surname><given-names>E.</given-names></name><name><surname>Carlstedt-Duke</surname><given-names>B.</given-names></name><name><surname>HÖVerstad</surname><given-names>T.</given-names></name><name><surname>Midtvedt</surname><given-names>A. C.</given-names></name><name><surname>Saxerholt</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>1990</year>). <article-title>Intestinal microbial conversion of cholesterol to coprostanol in man</article-title>. <source/>APMIS
<volume>98</volume>, <fpage>839</fpage>–<lpage>844</lpage>.  <pub-id pub-id-type="doi">10.1111/j.1699-0463.1990.tb05004.x</pub-id>
<pub-id pub-id-type="pmid">2223037</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miettinen</surname><given-names>T. A.</given-names></name></person-group> (<year>1979</year>). <article-title>Effects of neomycin alone and in combination with cholestyramine on serum cholesterol and fecal steroids in hypercholesterolemic subjects</article-title>. <source/>J. Clin. Invest.
<volume>64</volume>, <fpage>1485</fpage>–<lpage>1493</lpage>.  <pub-id pub-id-type="doi">10.1172/JCI109607</pub-id>
<pub-id pub-id-type="pmid">387820</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mistry</surname><given-names>R. H.</given-names></name><name><surname>Verkade</surname><given-names>H. J.</given-names></name><name><surname>Tietge</surname><given-names>U. J. F.</given-names></name></person-group> (<year>2017</year>). <article-title>Reverse Cholesterol Transport Is Increased in Germ-Free Mice-Brief Report</article-title>. <source/>Arterioscler. Thromb. Vasc. Biol.
<volume>37</volume>, <fpage>419</fpage>–<lpage>422</lpage>.  <pub-id pub-id-type="doi">10.1161/ATVBAHA.116.308306</pub-id>
<pub-id pub-id-type="pmid">28062491</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Netto Candido</surname><given-names>T. L.</given-names></name><name><surname>Bressan</surname><given-names>J.</given-names></name><name><surname>Alfenas</surname><given-names>R.de C.G.</given-names></name></person-group> (<year>2018</year>). <article-title>Dysbiosis and metabolic endotoxemia induced by high-fat diet</article-title>. <source/>Nutr. Hosp.
<volume>35</volume>, <fpage>1432</fpage>–<lpage>1440</lpage>.  <pub-id pub-id-type="doi">10.20960/nh.1792</pub-id>
<pub-id pub-id-type="pmid">30525859</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>J. K.</given-names></name><name><surname>Holmes</surname><given-names>E.</given-names></name><name><surname>Kinross</surname><given-names>J.</given-names></name><name><surname>Burcelin</surname><given-names>R.</given-names></name><name><surname>Gibson</surname><given-names>G.</given-names></name><name><surname>Jia</surname><given-names>W.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Host-Gut Microbiota Metabolic Interactions</article-title>. <source/>Science
<volume>336</volume>, <fpage>1262</fpage>–<lpage>1267</lpage>.  <pub-id pub-id-type="doi">10.1126/science.1223813</pub-id>
<pub-id pub-id-type="pmid">22674330</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nolan</surname><given-names>J. A.</given-names></name><name><surname>Skuse</surname><given-names>P.</given-names></name><name><surname>Govindarajan</surname><given-names>K.</given-names></name><name><surname>Patterson</surname><given-names>E.</given-names></name><name><surname>Konstantinidou</surname><given-names>N.</given-names></name><name><surname>Casey</surname><given-names>P. G.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>The influence of rosuvastatin on the gastrointestinal microbiota and host gene expression profiles</article-title>. <source/>Am. J. Physiol.-Gastrointest. Liver Physiol.
<volume>312</volume>, <fpage>G488</fpage>–<lpage>G497</lpage>.  <pub-id pub-id-type="doi">10.1152/ajpgi.00149.2016</pub-id>
<pub-id pub-id-type="pmid">28209601</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nuriel-Ohayon</surname><given-names>M.</given-names></name><name><surname>Neuman</surname><given-names>H.</given-names></name><name><surname>Koren</surname><given-names>O.</given-names></name></person-group> (<year>2016</year>). <article-title>Microbial Changes during Pregnancy, Birth, and Infancy</article-title>. <source/>Front. Microbiol.
<volume>7</volume>, <elocation-id>1031</elocation-id>.  <pub-id pub-id-type="doi">10.3389/fmicb.2016.01031</pub-id>
<pub-id pub-id-type="pmid">27471494</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Onaolapo</surname><given-names>O. J.</given-names></name><name><surname>Onaolapo</surname><given-names>A. Y.</given-names></name><name><surname>Olowe</surname><given-names>A. O.</given-names></name></person-group> (<year>2020</year>). <article-title>The neurobehavioral implications of the brain and microbiota interaction</article-title>. <source/>Front. Biosci. Landmark Ed.
<volume>25</volume>, <fpage>363</fpage>–<lpage>397</lpage>. <pub-id pub-id-type="doi">10.2741/4810</pub-id>
<pub-id pub-id-type="pmid">31585893</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Out</surname><given-names>C.</given-names></name><name><surname>Patankar</surname><given-names>J. V.</given-names></name><name><surname>Doktorova</surname><given-names>M.</given-names></name><name><surname>Boesjes</surname><given-names>M.</given-names></name><name><surname>Bos</surname><given-names>T.</given-names></name><name><surname>de Boer</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Gut microbiota inhibit Asbt-dependent intestinal bile acid reabsorption via Gata4</article-title>. <source/>J. Hepatol.
<volume>63</volume>, <fpage>697</fpage>–<lpage>704</lpage>.  <pub-id pub-id-type="doi">10.1016/j.jhep.2015.04.030</pub-id>
<pub-id pub-id-type="pmid">26022694</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pertovaara</surname><given-names>M.</given-names></name><name><surname>Raitala</surname><given-names>A.</given-names></name><name><surname>Juonala</surname><given-names>M.</given-names></name><name><surname>Lehtimäki</surname><given-names>T.</given-names></name><name><surname>Huhtala</surname><given-names>H.</given-names></name><name><surname>Oja</surname><given-names>S. S.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study: Indoleamine 2,3-dioxygenase and atherosclerosis</article-title>. <source/>Clin. Exp. Immunol.
<volume>148</volume>, <fpage>106</fpage>–<lpage>111</lpage>.  <pub-id pub-id-type="doi">10.1111/j.1365-2249.2007.03325.x</pub-id>
<pub-id pub-id-type="pmid">17349013</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Polyzos</surname><given-names>K. A.</given-names></name><name><surname>Ovchinnikova</surname><given-names>O.</given-names></name><name><surname>Berg</surname><given-names>M.</given-names></name><name><surname>Baumgartner</surname><given-names>R.</given-names></name><name><surname>Agardh</surname><given-names>H.</given-names></name><name><surname>Pirault</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Inhibition of indoleamine 2,3-dioxygenase promotes vascular inflammation and increases atherosclerosis in Apoe-/- mice</article-title>. <source/>Cardiovasc. Res.
<volume>106</volume>, <fpage>295</fpage>–<lpage>302</lpage>.  <pub-id pub-id-type="doi">10.1093/cvr/cvv100</pub-id>
<pub-id pub-id-type="pmid">25750192</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Poupon</surname><given-names>R. E.</given-names></name><name><surname>Ouguerram</surname><given-names>K.</given-names></name><name><surname>Chrétien</surname><given-names>Y.</given-names></name><name><surname>Verneau</surname><given-names>C.</given-names></name><name><surname>Eschwège</surname><given-names>E.</given-names></name><name><surname>Magot</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>1993</year>). <article-title>Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis</article-title>. <source/>Hepatol. Baltim. Md
<volume>17</volume>, <fpage>577</fpage>–<lpage>582</lpage>. <pub-id pub-id-type="doi">10.1002/hep.1840170408</pub-id>
</mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rabot</surname><given-names>S.</given-names></name><name><surname>Membrez</surname><given-names>M.</given-names></name><name><surname>Bruneau</surname><given-names>A.</given-names></name><name><surname>Gérard</surname><given-names>P.</given-names></name><name><surname>Harach</surname><given-names>T.</given-names></name><name><surname>Moser</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism</article-title>. <source/>FASEB J.
<volume>24</volume>, <fpage>4948</fpage>–<lpage>4959</lpage>.  <pub-id pub-id-type="doi">10.1096/fj.10-164921</pub-id>
<pub-id pub-id-type="pmid">20724524</pub-id></mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Randrianarisoa</surname><given-names>E.</given-names></name><name><surname>Lehn-Stefan</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Hoene</surname><given-names>M.</given-names></name><name><surname>Peter</surname><given-names>A.</given-names></name><name><surname>Heinzmann</surname><given-names>S. S.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Relationship of Serum Trimethylamine N-Oxide (TMAO) Levels with early Atherosclerosis in Humans</article-title>. <source/>Sci. Rep.
<volume>6</volume>, <fpage>26745</fpage>.  <pub-id pub-id-type="doi">10.1038/srep26745</pub-id>
<pub-id pub-id-type="pmid">27228955</pub-id></mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Riccioni</surname><given-names>G.</given-names></name><name><surname>Sblendorio</surname><given-names>V.</given-names></name><name><surname>Gemello</surname><given-names>E.</given-names></name><name><surname>Di Bello</surname><given-names>B.</given-names></name><name><surname>Scotti</surname><given-names>L.</given-names></name><name><surname>Cusenza</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Dietary Fibers and Cardiometabolic Diseases</article-title>. <source/>Int. J. Mol. Sci.
<volume>13</volume>, <fpage>1524</fpage>–<lpage>1540</lpage>.  <pub-id pub-id-type="doi">10.3390/ijms13021524</pub-id>
<pub-id pub-id-type="pmid">22408406</pub-id></mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ridlon</surname><given-names>J. M.</given-names></name><name><surname>Kang</surname><given-names>D. J.</given-names></name><name><surname>Hylemon</surname><given-names>P. B.</given-names></name><name><surname>Bajaj</surname><given-names>J. S.</given-names></name></person-group> (<year>2014</year>). <article-title>Bile acids and the gut microbiome</article-title>. <source/>Curr. Opin. Gastroenterol.
<volume>30</volume>, <fpage>332</fpage>–<lpage>338</lpage>.  <pub-id pub-id-type="doi">10.1097/MOG.0000000000000057</pub-id>
<pub-id pub-id-type="pmid">24625896</pub-id></mixed-citation>
</ref>
<ref id="B127">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Riggs</surname><given-names>M. G.</given-names></name><name><surname>Whittaker</surname><given-names>R. G.</given-names></name><name><surname>Neumann</surname><given-names>J. R.</given-names></name><name><surname>Ingram</surname><given-names>V. M.</given-names></name></person-group> (<year>1977</year>). <article-title>n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells</article-title>. <source/>Nature
<volume>268</volume>, <fpage>462</fpage>–<lpage>464</lpage>.  <pub-id pub-id-type="doi">10.1038/268462a0</pub-id>
<pub-id pub-id-type="pmid">268489</pub-id></mixed-citation>
</ref>
<ref id="B128">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ripsin</surname><given-names>C. M.</given-names></name><name><surname>Keenan</surname><given-names>J. M.</given-names></name><name><surname>Jacobs</surname><given-names>D. R.</given-names></name><name><surname>Elmer</surname><given-names>P. J.</given-names></name><name><surname>Welch</surname><given-names>R. R.</given-names></name><name><surname>Horn</surname><given-names>L. V.</given-names></name><etal></etal></person-group> (<year>1992</year>). <article-title>Oat Products and Lipid Lowering: A Meta-analysis</article-title>. <source/>JAMA
<volume>267</volume>, <fpage>3317</fpage>–<lpage>3325</lpage>.  <pub-id pub-id-type="doi">10.1001/jama.1992.03480240079039</pub-id>
<pub-id pub-id-type="pmid">1317928</pub-id></mixed-citation>
</ref>
<ref id="B129">
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Rodwell</surname><given-names>V. W.</given-names></name><name><surname>Nordstrom</surname><given-names>J. L.</given-names></name><name><surname>Mitschelen</surname><given-names>J. J.</given-names></name></person-group> (<year>1976</year>). “<article-title>Regulation of HMG-CoA Reductase</article-title>,” in <source/>Advances in Lipid Research. Eds. <person-group person-group-type="editor"><name><surname>Paoletti</surname><given-names>R.</given-names></name><name><surname>Kritchevsky</surname><given-names>D.</given-names></name></person-group> (<publisher-loc>London</publisher-loc>: <publisher-name>Elsevier, Academic Press Inc.</publisher-name>), <fpage>1</fpage>–<lpage>74</lpage>.  <pub-id pub-id-type="doi">10.1016/B978-0-12-024914-5.50008-5</pub-id>
</mixed-citation>
</ref>
<ref id="B130">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rothschild</surname><given-names>D.</given-names></name><name><surname>Weissbrod</surname><given-names>O.</given-names></name><name><surname>Barkan</surname><given-names>E.</given-names></name><name><surname>Kurilshikov</surname><given-names>A.</given-names></name><name><surname>Korem</surname><given-names>T.</given-names></name><name><surname>Zeevi</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Environment dominates over host genetics in shaping human gut microbiota</article-title>. <source/>Nature
<volume>555</volume>, <fpage>210</fpage>–<lpage>215</lpage>.  <pub-id pub-id-type="doi">10.1038/nature25973</pub-id>
<pub-id pub-id-type="pmid">29489753</pub-id></mixed-citation>
</ref>
<ref id="B132">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Samuel</surname><given-names>P.</given-names></name><name><surname>Whithe</surname><given-names>W. I.</given-names></name></person-group> (<year>1961</year>). <article-title>Reduction of serum cholesterol concentrations by neomycin, para-aminosalicylic acid, and other antibacterial drugs in man</article-title>. <source/>Circulation
<volume>24</volume>, <fpage>578</fpage>–<lpage>591</lpage>. <pub-id pub-id-type="doi">10.1161/01.CIR.24.3.578</pub-id>
<pub-id pub-id-type="pmid">13746005</pub-id></mixed-citation>
</ref>
<ref id="B131">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Samuel</surname><given-names>P.</given-names></name><name><surname>Holtzman</surname><given-names>C. M.</given-names></name><name><surname>Meilman</surname><given-names>E.</given-names></name><name><surname>Sekowski</surname><given-names>I.</given-names></name></person-group> (<year>1973</year>). <article-title>Effect of neomycin and other antibiotics on serum cholesterol levels and on 7alpha-dehydroxylation of bile acids by the fecal bacterial flora in man</article-title>. <source/>Circ. Res.
<volume>33</volume>, <fpage>393</fpage>–<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1161/01.RES.33.4.393</pub-id>
<pub-id pub-id-type="pmid">4741941</pub-id></mixed-citation>
</ref>
<ref id="B133">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sarin</surname><given-names>S. K.</given-names></name><name><surname>Pande</surname><given-names>A.</given-names></name><name><surname>Schnabl</surname><given-names>B.</given-names></name></person-group> (<year>2019</year>). <article-title>Microbiome as a therapeutic target in alcohol-related liver disease</article-title>. <source/>J. Hepatol.
<volume>70</volume>, <fpage>260</fpage>–<lpage>272</lpage>.  <pub-id pub-id-type="doi">10.1016/j.jhep.2018.10.019</pub-id>
<pub-id pub-id-type="pmid">30658727</pub-id></mixed-citation>
</ref>
<ref id="B134">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Savin</surname><given-names>Z.</given-names></name><name><surname>Kivity</surname><given-names>S.</given-names></name><name><surname>Yonath</surname><given-names>H.</given-names></name><name><surname>Yehuda</surname><given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Smoking and the intestinal microbiome</article-title>. <source/>Arch. Microbiol.
<volume>200</volume>, <fpage>677</fpage>–<lpage>684</lpage>.  <pub-id pub-id-type="doi">10.1007/s00203-018-1506-2</pub-id>
<pub-id pub-id-type="pmid">29626219</pub-id></mixed-citation>
</ref>
<ref id="B135">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sayin</surname><given-names>S. I.</given-names></name><name><surname>Wahlström</surname><given-names>A.</given-names></name><name><surname>Felin</surname><given-names>J.</given-names></name><name><surname>Jäntti</surname><given-names>S.</given-names></name><name><surname>Marschall</surname><given-names>H.-U.</given-names></name><name><surname>Bamberg</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist</article-title>. <source/>Cell Metab.
<volume>17</volume>, <fpage>225</fpage>–<lpage>235</lpage>.  <pub-id pub-id-type="doi">10.1016/j.cmet.2013.01.003</pub-id>
<pub-id pub-id-type="pmid">23395169</pub-id></mixed-citation>
</ref>
<ref id="B136">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schoeler</surname><given-names>M.</given-names></name><name><surname>Caesar</surname><given-names>R.</given-names></name></person-group> (<year>2019</year>). <article-title>Dietary lipids, gut microbiota and lipid metabolism</article-title>. <source/>Rev. Endocr. Metab. Disord. <volume>20</volume> (<issue>4</issue>), <fpage>461</fpage>–<lpage>472</lpage>.  <pub-id pub-id-type="doi">10.1007/s11154-019-09512-0</pub-id>
<pub-id pub-id-type="pmid">31707624</pub-id></mixed-citation>
</ref>
<ref id="B137">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sekimoto</surname><given-names>H.</given-names></name><name><surname>Shimada</surname><given-names>O.</given-names></name><name><surname>Makanishi</surname><given-names>M.</given-names></name><name><surname>Nakano</surname><given-names>T.</given-names></name><name><surname>Katayama</surname><given-names>O.</given-names></name></person-group> (<year>1983</year>). <article-title>Interrelationship between serum and fecal sterols</article-title>. <source/>Jpn. J. Med.
<volume>22</volume>, <fpage>14</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.2169/internalmedicine1962.22.14</pub-id>
<pub-id pub-id-type="pmid">6302358</pub-id></mixed-citation>
</ref>
<ref id="B138">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sekirov</surname><given-names>I.</given-names></name><name><surname>Russell</surname><given-names>S. L.</given-names></name><name><surname>Antunes</surname><given-names>L. C. M.</given-names></name><name><surname>Finlay</surname><given-names>B. B.</given-names></name></person-group> (<year>2010</year>). <article-title>Gut Microbiota in Health and Disease</article-title>. <source/>Physiol. Rev.
<volume>90</volume>, <fpage>859</fpage>–<lpage>904</lpage>.  <pub-id pub-id-type="doi">10.1152/physrev.00045.2009</pub-id>
<pub-id pub-id-type="pmid">20664075</pub-id></mixed-citation>
</ref>
<ref id="B139">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Silbernagel</surname><given-names>G.</given-names></name><name><surname>Fauler</surname><given-names>G.</given-names></name><name><surname>Hoffmann</surname><given-names>M. M.</given-names></name><name><surname>Lütjohann</surname><given-names>D.</given-names></name><name><surname>Winkelmann</surname><given-names>B. R.</given-names></name><name><surname>Boehm</surname><given-names>B. O.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>The associations of cholesterol metabolism and plasma plant sterols with all-cause and cardiovascular mortality</article-title>. <source/>J. Lipid Res.
<volume>51</volume>, <fpage>2384</fpage>–<lpage>2393</lpage>.  <pub-id pub-id-type="doi">10.1194/jlr.P002899</pub-id>
<pub-id pub-id-type="pmid">20228406</pub-id></mixed-citation>
</ref>
<ref id="B140">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>A. B.</given-names></name><name><surname>Dong</surname><given-names>B.</given-names></name><name><surname>Kraemer</surname><given-names>F. B.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice</article-title>. <source/>Arterioscler. Thromb. Vasc. Biol.
<volume>38</volume>, <fpage>2448</fpage>–<lpage>2459</lpage>.  <pub-id pub-id-type="doi">10.1161/ATVBAHA.118.311122</pub-id>
<pub-id pub-id-type="pmid">30354208</pub-id></mixed-citation>
</ref>
<ref id="B141">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sivan</surname><given-names>A.</given-names></name><name><surname>Corrales</surname><given-names>L.</given-names></name><name><surname>Hubert</surname><given-names>N.</given-names></name><name><surname>Williams</surname><given-names>J. B.</given-names></name><name><surname>Aquino-Michaels</surname><given-names>K.</given-names></name><name><surname>Earley</surname><given-names>Z. M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy</article-title>. <source/>Science
<volume>350</volume>, <fpage>1084</fpage>–<lpage>1089</lpage>.  <pub-id pub-id-type="doi">10.1126/science.aac4255</pub-id>
<pub-id pub-id-type="pmid">26541606</pub-id></mixed-citation>
</ref>
<ref id="B142">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spanogiannopoulos</surname><given-names>P.</given-names></name><name><surname>Bess</surname><given-names>E. N.</given-names></name><name><surname>Carmody</surname><given-names>R. N.</given-names></name><name><surname>Turnbaugh</surname><given-names>P. J.</given-names></name></person-group> (<year>2016</year>). <article-title>The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism</article-title>. <source/>Nat. Rev. Microbiol.
<volume>14</volume>, <fpage>273</fpage>–<lpage>287</lpage>.  <pub-id pub-id-type="doi">10.1038/nrmicro.2016.17</pub-id>
<pub-id pub-id-type="pmid">26972811</pub-id></mixed-citation>
</ref>
<ref id="B143">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spinelli</surname><given-names>V.</given-names></name><name><surname>Chávez-Talavera</surname><given-names>O.</given-names></name><name><surname>Tailleux</surname><given-names>A.</given-names></name><name><surname>Staels</surname><given-names>B.</given-names></name></person-group> (<year>2016</year>). <article-title>Metabolic effects of bile acid sequestration: impact on cardiovascular risk factors</article-title>. <source/>Curr. Opin. Endocrinol. Diabetes Obes.
<volume>23</volume>, <fpage>138</fpage>–<lpage>144</lpage>.  <pub-id pub-id-type="doi">10.1097/MED.0000000000000235</pub-id>
<pub-id pub-id-type="pmid">26859552</pub-id></mixed-citation>
</ref>
<ref id="B144">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sridharan</surname><given-names>G. V.</given-names></name><name><surname>Choi</surname><given-names>K.</given-names></name><name><surname>Klemashevich</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Prabakaran</surname><given-names>D.</given-names></name><name><surname>Pan</surname><given-names>L. B.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Prediction and quantification of bioactive microbiota metabolites in the mouse gut</article-title>. <source/>Nat. Commun.
<volume>5</volume>, <fpage>5492</fpage>.  <pub-id pub-id-type="doi">10.1038/ncomms6492</pub-id>
<pub-id pub-id-type="pmid">25411059</pub-id></mixed-citation>
</ref>
<ref id="B145">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stepankova</surname><given-names>R.</given-names></name><name><surname>Tonar</surname><given-names>Z.</given-names></name><name><surname>Bartova</surname><given-names>J.</given-names></name><name><surname>Nedorost</surname><given-names>L.</given-names></name><name><surname>Rossman</surname><given-names>P.</given-names></name><name><surname>Poledne</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Absence of microbiota (germ-free conditions) accelerates the atherosclerosis in ApoE-deficient mice fed standard low cholesterol diet</article-title>. <source/>J. Atheroscler. Thromb.
<volume>17</volume>, <fpage>796</fpage>–<lpage>804</lpage>. <pub-id pub-id-type="doi">10.5551/jat.3285</pub-id>
<pub-id pub-id-type="pmid">20379054</pub-id></mixed-citation>
</ref>
<ref id="B146">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stone</surname><given-names>N. J.</given-names></name><name><surname>Robinson</surname><given-names>J. G.</given-names></name><name><surname>Lichtenstein</surname><given-names>A. H.</given-names></name><name><surname>Bairey Merz</surname><given-names>C. N.</given-names></name><name><surname>Blum</surname><given-names>C. B.</given-names></name><name><surname>Eckel</surname><given-names>R. H.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults</article-title>. <source/>J. Am. Coll. Cardiol.
<volume>63</volume>, <fpage>2889</fpage>–<lpage>2934</lpage>.  <pub-id pub-id-type="doi">10.1016/j.jacc.2013.11.002</pub-id>
<pub-id pub-id-type="pmid">24239923</pub-id></mixed-citation>
</ref>
<ref id="B147">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stroes</surname><given-names>E. S.</given-names></name><name><surname>Thompson</surname><given-names>P. D.</given-names></name><name><surname>Corsini</surname><given-names>A.</given-names></name><name><surname>Vladutiu</surname><given-names>G. D.</given-names></name><name><surname>Raal</surname><given-names>F. J.</given-names></name><name><surname>Ray</surname><given-names>K. K.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management</article-title>. <source/>Eur. Heart J.
<volume>36</volume>, <fpage>1012</fpage>–<lpage>1022</lpage>.  <pub-id pub-id-type="doi">10.1093/eurheartj/ehv043</pub-id>
<pub-id pub-id-type="pmid">25694464</pub-id></mixed-citation>
</ref>
<ref id="B149">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sun</surname><given-names>M.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Cong</surname><given-names>Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases</article-title>. <source/>J. Gastroenterol.
<volume>52</volume>, <fpage>1</fpage>–<lpage>8</lpage>.  <pub-id pub-id-type="doi">10.1007/s00535-016-1242-9</pub-id>
<pub-id pub-id-type="pmid">27448578</pub-id></mixed-citation>
</ref>
<ref id="B148">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sun</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name></person-group> (<year>2018</year>). <article-title>Comparative analysis of the gut microbiota in distinct statin response patients in East China</article-title>. <source/>J. Microbiol. Seoul Korea
<volume>56</volume>, <fpage>886</fpage>–<lpage>892</lpage>.  <pub-id pub-id-type="doi">10.1007/s12275-018-8152-x</pub-id>
</mixed-citation>
</ref>
<ref id="B150">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Surakka</surname><given-names>I.</given-names></name><name><surname>Horikoshi</surname><given-names>M.</given-names></name><name><surname>Mägi</surname><given-names>R.</given-names></name><name><surname>Sarin</surname><given-names>A.-P.</given-names></name><name><surname>Mahajan</surname><given-names>A.</given-names></name><name><surname>Lagou</surname><given-names>V.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>The impact of low-frequency and rare variants on lipid levels</article-title>. <source/>Nat. Genet.
<volume>47</volume>, <fpage>589</fpage>–<lpage>597</lpage>.  <pub-id pub-id-type="doi">10.1038/ng.3300</pub-id>
<pub-id pub-id-type="pmid">25961943</pub-id></mixed-citation>
</ref>
<ref id="B151">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takikawa</surname><given-names>H.</given-names></name><name><surname>Otsuka</surname><given-names>H.</given-names></name><name><surname>Beppu</surname><given-names>T.</given-names></name><name><surname>Seyama</surname><given-names>Y.</given-names></name><name><surname>Yamakawa</surname><given-names>T.</given-names></name></person-group> (<year>1983</year>). <article-title>Serum concentrations of bile acid glucuronides in hepatobiliary diseases</article-title>. <source/>Digestion
<volume>27</volume>, <fpage>189</fpage>–<lpage>195</lpage>.  <pub-id pub-id-type="doi">10.1159/000198952</pub-id>
<pub-id pub-id-type="pmid">6653918</pub-id></mixed-citation>
</ref>
<ref id="B152">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taleb</surname><given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Tryptophan Dietary Impacts Gut Barrier and Metabolic Diseases</article-title>. <source/>Front. Immunol.
<volume>10</volume> (<issue>2113</issue>).  <pub-id pub-id-type="doi">10.3389/fimmu.2019.02113</pub-id>
</mixed-citation>
</ref>
<ref id="B153">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tang</surname><given-names>W. H. W.</given-names></name><name><surname>Kitai</surname><given-names>T.</given-names></name><name><surname>Hazen</surname><given-names>S. L.</given-names></name></person-group> (<year>2017</year>). <article-title>Gut Microbiota in Cardiovascular Health and Disease</article-title>. <source/>Circ. Res.
<volume>120</volume>, <fpage>1183</fpage>–<lpage>1196</lpage>.  <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.309715</pub-id>
<pub-id pub-id-type="pmid">28360349</pub-id></mixed-citation>
</ref>
<ref id="B154">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thomas</surname><given-names>C.</given-names></name><name><surname>Pellicciari</surname><given-names>R.</given-names></name><name><surname>Pruzanski</surname><given-names>M.</given-names></name><name><surname>Auwerx</surname><given-names>J.</given-names></name><name><surname>Schoonjans</surname><given-names>K.</given-names></name></person-group> (<year>2008</year>). <article-title>Targeting bile-acid signalling for metabolic diseases</article-title>. <source/>Nat. Rev. Drug Discovery
<volume>7</volume>, <fpage>678</fpage>–<lpage>693</lpage>.  <pub-id pub-id-type="doi">10.1038/nrd2619</pub-id>
<pub-id pub-id-type="pmid">18670431</pub-id></mixed-citation>
</ref>
<ref id="B155">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tong</surname><given-names>A.-J.</given-names></name><name><surname>Hu</surname><given-names>R.-K.</given-names></name><name><surname>Wu</surname><given-names>L.-X.</given-names></name><name><surname>Lv</surname><given-names>X.-C.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>L.-N.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Ganoderma polysaccharide and chitosan synergistically ameliorate lipid metabolic disorders and modulate gut microbiota composition in high fat diet-fed golden hamsters</article-title>. <source/>J. Food Biochem., <elocation-id>e13109</elocation-id>.  <pub-id pub-id-type="doi">10.1111/jfbc.13109</pub-id>
<pub-id pub-id-type="pmid">31793675</pub-id></mixed-citation>
</ref>
<ref id="B156">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tran</surname><given-names>T. T. T.</given-names></name><name><surname>Corsini</surname><given-names>S.</given-names></name><name><surname>Kellingray</surname><given-names>L.</given-names></name><name><surname>Hegarty</surname><given-names>C.</given-names></name><name><surname>Le Gall</surname><given-names>G.</given-names></name><name><surname>Narbad</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>APOE genotype influences the gut microbiome structure and function in humans and mice: relevance for Alzheimer’s disease pathophysiology</article-title>. <source/>FASEB J. <volume>33</volume> (<issue>7</issue>), <fpage>8221</fpage>–<lpage>8231</lpage>.  <pub-id pub-id-type="doi">10.1096/fj.201900071R</pub-id>
<pub-id pub-id-type="pmid">30958695</pub-id></mixed-citation>
</ref>
<ref id="B157">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsuji</surname><given-names>S.</given-names></name><name><surname>Suruda</surname><given-names>C.</given-names></name><name><surname>Hashiyada</surname><given-names>M.</given-names></name><name><surname>Kimata</surname><given-names>T.</given-names></name><name><surname>Yamanouchi</surname><given-names>S.</given-names></name><name><surname>Kitao</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Gut Microbiota Dysbiosis in Children with Relapsing Idiopathic Nephrotic Syndrome</article-title>. <source/>Am. J. Nephrol.
<volume>47</volume>, <fpage>164</fpage>–<lpage>170</lpage>.  <pub-id pub-id-type="doi">10.1159/000487557</pub-id>
<pub-id pub-id-type="pmid">29533950</pub-id></mixed-citation>
</ref>
<ref id="B158">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ussar</surname><given-names>S.</given-names></name><name><surname>Griffin</surname><given-names>N. W.</given-names></name><name><surname>Bezy</surname><given-names>O.</given-names></name><name><surname>Fujisaka</surname><given-names>S.</given-names></name><name><surname>Vienberg</surname><given-names>S.</given-names></name><name><surname>Softic</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Interactions between Gut Microbiota, Host Genetics and Diet Modulate the Predisposition to Obesity and Metabolic Syndrome</article-title>. <source/>Cell Metab.
<volume>22</volume>, <fpage>516</fpage>–<lpage>530</lpage>.  <pub-id pub-id-type="doi">10.1016/j.cmet.2015.07.007</pub-id>
<pub-id pub-id-type="pmid">26299453</pub-id></mixed-citation>
</ref>
<ref id="B159">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vahouny</surname><given-names>G. V.</given-names></name><name><surname>Tombes</surname><given-names>R.</given-names></name><name><surname>Cassidy</surname><given-names>M. M.</given-names></name><name><surname>Kritchevsky</surname><given-names>D.</given-names></name><name><surname>Gallo</surname><given-names>L. L.</given-names></name></person-group> (<year>1980</year>). <article-title>Dietary fibers: V. Binding of bile salts, phospholipids and cholesterol from mixed micelles by bile acid sequestrants and dietary fibers</article-title>. <source/>Lipids
<volume>15</volume>, <fpage>1012</fpage>–<lpage>1018</lpage>.  <pub-id pub-id-type="doi">10.1007/BF02534316</pub-id>
<pub-id pub-id-type="pmid">6261073</pub-id></mixed-citation>
</ref>
<ref id="B160">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van Dongen</surname><given-names>J.</given-names></name><name><surname>Willemsen</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>W.-M.</given-names></name><name><surname>de Geus</surname><given-names>E. J. C.</given-names></name><name><surname>Boomsma</surname><given-names>D. I.</given-names></name></person-group> (<year>2013</year>). <article-title>Heritability of metabolic syndrome traits in a large population-based sample</article-title>. <source/>J. Lipid Res.
<volume>54</volume>, <fpage>2914</fpage>–<lpage>2923</lpage>.  <pub-id pub-id-type="doi">10.1194/jlr.P041673</pub-id>
<pub-id pub-id-type="pmid">23918046</pub-id></mixed-citation>
</ref>
<ref id="B161">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Veeravalli</surname><given-names>S.</given-names></name><name><surname>Karu</surname><given-names>K.</given-names></name><name><surname>Scott</surname><given-names>F.</given-names></name><name><surname>Fennema</surname><given-names>D.</given-names></name><name><surname>Phillips</surname><given-names>I. R.</given-names></name><name><surname>Shephard</surname><given-names>E. A.</given-names></name></person-group> (<year>2018</year>). <article-title>Effect of Flavin-Containing Monooxygenase Genotype, Mouse Strain, and Gender on Trimethylamine N-oxide Production, Plasma Cholesterol Concentration, and an Index of Atherosclerosis</article-title>. <source/>Drug Metab. Dispos.
<volume>46</volume>, <fpage>20</fpage>–<lpage>25</lpage>.  <pub-id pub-id-type="doi">10.1124/dmd.117.077636</pub-id>
<pub-id pub-id-type="pmid">29070510</pub-id></mixed-citation>
</ref>
<ref id="B162">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Veiga</surname><given-names>P.</given-names></name><name><surname>Juste</surname><given-names>C.</given-names></name><name><surname>Lepercq</surname><given-names>P.</given-names></name><name><surname>Saunier</surname><given-names>K.</given-names></name><name><surname>Béguet</surname><given-names>F.</given-names></name><name><surname>Gérard</surname><given-names>P.</given-names></name></person-group> (<year>2005</year>). <article-title>Correlation between faecal microbial community structure and cholesterol-to-coprostanol conversion in the human gut</article-title>. <source/>FEMS Microbiol. Lett.
<volume>242</volume>, <fpage>81</fpage>–<lpage>86</lpage>.  <pub-id pub-id-type="doi">10.1016/j.femsle.2004.10.042</pub-id>
<pub-id pub-id-type="pmid">15621423</pub-id></mixed-citation>
</ref>
<ref id="B163">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Velagapudi</surname><given-names>V. R.</given-names></name><name><surname>Hezaveh</surname><given-names>R.</given-names></name><name><surname>Reigstad</surname><given-names>C. S.</given-names></name><name><surname>Gopalacharyulu</surname><given-names>P.</given-names></name><name><surname>Yetukuri</surname><given-names>L.</given-names></name><name><surname>Islam</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>The gut microbiota modulates host energy and lipid metabolism in mice</article-title>. <source/>J. Lipid Res.
<volume>51</volume>, <fpage>1101</fpage>–<lpage>1112</lpage>.  <pub-id pub-id-type="doi">10.1194/jlr.M002774</pub-id>
<pub-id pub-id-type="pmid">20040631</pub-id></mixed-citation>
</ref>
<ref id="B164">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Venter</surname><given-names>C. S.</given-names></name><name><surname>Vorster</surname><given-names>H. H.</given-names></name><name><surname>Cummings</surname><given-names>J. H.</given-names></name></person-group> (<year>1990</year>). <article-title>Effects of dietary propionate on carbohydrate and lipid metabolism in healthy volunteers</article-title>. <source/>Am. J. Gastroenterol.
<volume>85</volume>, <fpage>549</fpage>–<lpage>553</lpage>.<pub-id pub-id-type="pmid">2159696</pub-id></mixed-citation>
</ref>
<ref id="B165">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vieira-Silva</surname><given-names>S.</given-names></name><name><surname>Sabino</surname><given-names>J.</given-names></name><name><surname>Valles-Colomer</surname><given-names>M.</given-names></name><name><surname>Falony</surname><given-names>G.</given-names></name><name><surname>Kathagen</surname><given-names>G.</given-names></name><name><surname>Caenepeel</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC/IBD diagnoses</article-title>. <source/>Nat. Microbiol.
<volume>4</volume>, <fpage>1826</fpage>–<lpage>1831</lpage>.  <pub-id pub-id-type="doi">10.1038/s41564-019-0483-9</pub-id>
<pub-id pub-id-type="pmid">31209308</pub-id></mixed-citation>
</ref>
<ref id="B166">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Jones</surname><given-names>P. J. H.</given-names></name><name><surname>Woollett</surname><given-names>L. A.</given-names></name><name><surname>Buckley</surname><given-names>D. D.</given-names></name><name><surname>Yao</surname><given-names>L.</given-names></name><name><surname>Granholm</surname><given-names>N. A.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>Effects of chenodeoxycholic acid and deoxycholic acid on cholesterol absorption and metabolism in humans</article-title>. <source/>Transl. Res. J. Lab. Clin. Med.
<volume>148</volume>, <fpage>37</fpage>–<lpage>45</lpage>.  <pub-id pub-id-type="doi">10.1016/j.lab.2006.03.009</pub-id>
</mixed-citation>
</ref>
<ref id="B167">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Klipfell</surname><given-names>E.</given-names></name><name><surname>Bennett</surname><given-names>B. J.</given-names></name><name><surname>Koeth</surname><given-names>R.</given-names></name><name><surname>Levison</surname><given-names>B. S.</given-names></name><name><surname>DuGar</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease</article-title>. <source/>Nature
<volume>472</volume>, <fpage>57</fpage>–<lpage>63</lpage>.  <pub-id pub-id-type="doi">10.1038/nature09922</pub-id>
<pub-id pub-id-type="pmid">21475195</pub-id></mixed-citation>
</ref>
<ref id="B168">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>M.</given-names></name><name><surname>Fukiya</surname><given-names>S.</given-names></name><name><surname>Yokota</surname><given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Comprehensive evaluation of the bactericidal activities of free bile acids in the large intestine of humans and rodents</article-title>. <source/>J. Lipid Res.
<volume>58</volume>, <fpage>1143</fpage>–<lpage>1152</lpage>.  <pub-id pub-id-type="doi">10.1194/jlr.M075143</pub-id>
<pub-id pub-id-type="pmid">28404640</pub-id></mixed-citation>
</ref>
<ref id="B169">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weingärtner</surname><given-names>O.</given-names></name><name><surname>Lütjohann</surname><given-names>D.</given-names></name><name><surname>Vanmierlo</surname><given-names>T.</given-names></name><name><surname>Müller</surname><given-names>S.</given-names></name><name><surname>Günther</surname><given-names>L.</given-names></name><name><surname>Herrmann</surname><given-names>W.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Markers of enhanced cholesterol absorption are a strong predictor for cardiovascular diseases in patients without diabetes mellitus</article-title>. <source/>Chem. Phys. Lipids
<volume>164</volume>, <fpage>451</fpage>–<lpage>456</lpage>.  <pub-id pub-id-type="doi">10.1016/j.chemphyslip.2011.03.008</pub-id>
<pub-id pub-id-type="pmid">21501602</pub-id></mixed-citation>
</ref>
<ref id="B170">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wikoff</surname><given-names>W. R.</given-names></name><name><surname>Anfora</surname><given-names>A. T.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Schultz</surname><given-names>P. G.</given-names></name><name><surname>Lesley</surname><given-names>S. A.</given-names></name><name><surname>Peters</surname><given-names>E. C.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites</article-title>. <source/>Proc. Natl. Acad. Sci.
<volume>106</volume>, <fpage>3698</fpage>–<lpage>3703</lpage>.  <pub-id pub-id-type="doi">10.1073/pnas.0812874106</pub-id>
<pub-id pub-id-type="pmid">19234110</pub-id></mixed-citation>
</ref>
<ref id="B171">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wilkins</surname><given-names>T. D.</given-names></name><name><surname>Hackman</surname><given-names>A. S.</given-names></name></person-group> (<year>1974</year>). <article-title>Two Patterns of Neutral Steroid Conversion in the Feces of Normal North Americans</article-title>. <source/>Cancer Res.
<volume>34</volume> (<issue>9</issue>), <fpage>2250</fpage>–<lpage>2254</lpage>.<pub-id pub-id-type="pmid">4843533</pub-id></mixed-citation>
</ref>
<ref id="B172">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Willer</surname><given-names>C. J.</given-names></name><name><surname>Schmidt</surname><given-names>E. M.</given-names></name><name><surname>Sengupta</surname><given-names>S.</given-names></name><name><surname>Peloso</surname><given-names>G. M.</given-names></name><name><surname>Gustafsson</surname><given-names>S.</given-names></name><name><surname>Kanoni</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Discovery and refinement of loci associated with lipid levels</article-title>. <source/>Nat. Genet.
<volume>45</volume>, <fpage>1274</fpage>–<lpage>1283</lpage>.  <pub-id pub-id-type="doi">10.1038/ng.2797</pub-id>
<pub-id pub-id-type="pmid">24097068</pub-id></mixed-citation>
</ref>
<ref id="B173">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wilson</surname><given-names>I. D.</given-names></name><name><surname>Nicholson</surname><given-names>J. K.</given-names></name></person-group> (<year>2017</year>). <article-title>Gut microbiome interactions with drug metabolism, efficacy, and toxicity</article-title>. <source/>Transl. Res.
<volume>179</volume>, <fpage>204</fpage>–<lpage>222</lpage>.  <pub-id pub-id-type="doi">10.1016/j.trsl.2016.08.002</pub-id>
<pub-id pub-id-type="pmid">27591027</pub-id></mixed-citation>
</ref>
<ref id="B174">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wisniewski</surname><given-names>P. J.</given-names></name><name><surname>Dowden</surname><given-names>R. A.</given-names></name><name><surname>Campbell</surname><given-names>S. C.</given-names></name></person-group> (<year>2019</year>). <article-title>Role of Dietary Lipids in Modulating Inflammation through the Gut Microbiota</article-title>. <source/>Nutrients
<volume>11</volume>, <fpage>1</fpage>–<lpage>30</lpage>.  <pub-id pub-id-type="doi">10.3390/nu11010117</pub-id>
</mixed-citation>
</ref>
<ref id="B175">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wolever</surname><given-names>T. M. S.</given-names></name><name><surname>Spadafora</surname><given-names>P.</given-names></name><name><surname>Eshuis</surname><given-names>H.</given-names></name></person-group> (<year>1991</year>). <article-title>Interaction between colonic acetate and propionate in humans</article-title>. <source/>Am. J. Clin. Nutr.
<volume>53</volume>, <fpage>681</fpage>–<lpage>687</lpage>.  <pub-id pub-id-type="doi">10.1093/ajcn/53.3.681</pub-id>
<pub-id pub-id-type="pmid">2000822</pub-id></mixed-citation>
</ref>
<ref id="B176">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wolf</surname><given-names>D.</given-names></name><name><surname>Ley</surname><given-names>K.</given-names></name></person-group> (<year>2019</year>). <article-title>Immunity and Inflammation in Atherosclerosis</article-title>. <source/>Circ. Res.
<volume>124</volume>, <fpage>315</fpage>–<lpage>327</lpage>.  <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.118.313591</pub-id>
<pub-id pub-id-type="pmid">30653442</pub-id></mixed-citation>
</ref>
<ref id="B177">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wright</surname><given-names>S. D.</given-names></name><name><surname>Burton</surname><given-names>C.</given-names></name><name><surname>Hernandez</surname><given-names>M.</given-names></name><name><surname>Hassing</surname><given-names>H.</given-names></name><name><surname>Montenegro</surname><given-names>J.</given-names></name><name><surname>Mundt</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2000</year>). <article-title>Infectious Agents Are Not Necessary for Murine Atherogenesis</article-title>. <source/>J. Exp. Med.
<volume>191</volume>, <fpage>1437</fpage>–<lpage>1442</lpage>.  <pub-id pub-id-type="doi">10.1084/jem.191.8.1437</pub-id>
<pub-id pub-id-type="pmid">10770809</pub-id></mixed-citation>
</ref>
<ref id="B178">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>G. D.</given-names></name><name><surname>Compher</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>E. Z.</given-names></name><name><surname>Smith</surname><given-names>S. A.</given-names></name><name><surname>Shah</surname><given-names>R. D.</given-names></name><name><surname>Bittinger</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Comparative metabolomics in vegans and omnivores reveal constraints on diet-dependent gut microbiota metabolite production</article-title>. <source/>Gut
<volume>65</volume>, <fpage>63</fpage>–<lpage>72</lpage>.  <pub-id pub-id-type="doi">10.1136/gutjnl-2014-308209</pub-id>
<pub-id pub-id-type="pmid">25431456</pub-id></mixed-citation>
</ref>
<ref id="B179">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Zhao</surname><given-names>R.</given-names></name><name><surname>Pan</surname><given-names>X.</given-names></name><name><surname>Liang</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Gut Microbiota-Dependent Marker TMAO in Promoting Cardiovascular Disease: Inflammation Mechanism, Clinical Prognostic, and Potential as a Therapeutic Target</article-title>. <source/>Front. Pharmacol.
<volume>10</volume> (<issue>1360</issue>).  <pub-id pub-id-type="doi">10.3389/fphar.2019.01360</pub-id>
</mixed-citation>
</ref>
<ref id="B180">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoo</surname><given-names>D.-H.</given-names></name><name><surname>Kim</surname><given-names>I. S.</given-names></name><name><surname>Le</surname><given-names>T. K. V.</given-names></name><name><surname>Jung</surname><given-names>I.-H.</given-names></name><name><surname>Yoo</surname><given-names>H. H.</given-names></name><name><surname>Kim</surname><given-names>D.-H.</given-names></name></person-group> (<year>2014</year>). <article-title>Gut Microbiota-Mediated Drug Interactions between Lovastatin and Antibiotics</article-title>. <source/>Drug Metab. Dispos.
<volume>42</volume>, <fpage>1508</fpage>–<lpage>1513</lpage>.  <pub-id pub-id-type="doi">10.1124/dmd.114.058354</pub-id>
<pub-id pub-id-type="pmid">24947972</pub-id></mixed-citation>
</ref>
<ref id="B181">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoshii</surname><given-names>K.</given-names></name><name><surname>Hosomi</surname><given-names>K.</given-names></name><name><surname>Sawane</surname><given-names>K.</given-names></name><name><surname>Kunisawa</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>Metabolism of Dietary and Microbial Vitamin B Family in the Regulation of Host Immunity</article-title>. <source/>Front. Nutr.
<volume>6</volume>, <elocation-id>48</elocation-id>.  <pub-id pub-id-type="doi">10.3389/fnut.2019.00048</pub-id>
<pub-id pub-id-type="pmid">31058161</pub-id></mixed-citation>
</ref>
<ref id="B182">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Wyszynski</surname><given-names>D. F.</given-names></name><name><surname>Waterworth</surname><given-names>D. M.</given-names></name><name><surname>Wilton</surname><given-names>S. D.</given-names></name><name><surname>Barter</surname><given-names>P. J.</given-names></name><name><surname>Kesäniemi</surname><given-names>Y. A.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia</article-title>. <source/>J. Lipid Res.
<volume>46</volume>, <fpage>2202</fpage>–<lpage>2213</lpage>.  <pub-id pub-id-type="doi">10.1194/jlr.M500137-JLR200</pub-id>
<pub-id pub-id-type="pmid">16061952</pub-id></mixed-citation>
</ref>
<ref id="B183">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yusuf</surname><given-names>S.</given-names></name><name><surname>Hawken</surname><given-names>S.</given-names></name><name><surname>Ounpuu</surname><given-names>S.</given-names></name><name><surname>Dans</surname><given-names>T.</given-names></name><name><surname>Avezum</surname><given-names>A.</given-names></name><name><surname>Lanas</surname><given-names>F.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study</article-title>. <source/>Lancet Lond. Engl.
<volume>364</volume>, <fpage>937</fpage>–<lpage>952</lpage>.  <pub-id pub-id-type="doi">10.1016/S0140-6736(04)17018-9</pub-id>
</mixed-citation>
</ref>
<ref id="B184">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zarrinpar</surname><given-names>A.</given-names></name><name><surname>Chaix</surname><given-names>A.</given-names></name><name><surname>Xu</surname><given-names>Z. Z.</given-names></name><name><surname>Chang</surname><given-names>M. W.</given-names></name><name><surname>Marotz</surname><given-names>C. A.</given-names></name><name><surname>Saghatelian</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Antibiotic-induced microbiome depletion alters metabolic homeostasis by affecting gut signaling and colonic metabolism</article-title>. <source/>Nat. Commun.
<volume>9</volume>, <fpage>2872</fpage>.  <pub-id pub-id-type="doi">10.1038/s41467-018-05336-9</pub-id>
<pub-id pub-id-type="pmid">30030441</pub-id></mixed-citation>
</ref>
<ref id="B185">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Ovchinnikova</surname><given-names>O.</given-names></name><name><surname>Jönsson</surname><given-names>A.</given-names></name><name><surname>Lundberg</surname><given-names>A. M.</given-names></name><name><surname>Berg</surname><given-names>M.</given-names></name><name><surname>Hansson</surname><given-names>G. K.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice</article-title>. <source/>Eur. Heart J.
<volume>33</volume>, <fpage>2025</fpage>–<lpage>2034</lpage>.  <pub-id pub-id-type="doi">10.1093/eurheartj/ehs175</pub-id>
<pub-id pub-id-type="pmid">22711758</pub-id></mixed-citation>
</ref>
<ref id="B186">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Hao</surname><given-names>W.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Liang</surname><given-names>N.</given-names></name><name><surname>He</surname><given-names>Z.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Structure-Specific Effects of Short-Chain Fatty Acids on Plasma Cholesterol Concentration in Male Syrian Hamsters</article-title>. <source/>J. Agric. Food Chem.
<volume>65</volume>, <fpage>10984</fpage>–<lpage>10992</lpage>.  <pub-id pub-id-type="doi">10.1021/acs.jafc.7b04666</pub-id>
<pub-id pub-id-type="pmid">29190422</pub-id></mixed-citation>
</ref>
<ref id="B187">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhernakova</surname><given-names>A.</given-names></name><name><surname>Kurilshikov</surname><given-names>A.</given-names></name><name><surname>Bonder</surname><given-names>M. J.</given-names></name><name><surname>Tigchelaar</surname><given-names>E. F.</given-names></name><name><surname>Schirmer</surname><given-names>M.</given-names></name><name><surname>Vatanen</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity</article-title>. <source/>Science
<volume>352</volume>, <fpage>565</fpage>–<lpage>569</lpage>.  <pub-id pub-id-type="doi">10.1126/science.aad3369</pub-id>
<pub-id pub-id-type="pmid">27126040</pub-id></mixed-citation>
</ref>
<ref id="B188">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhernakova</surname><given-names>D. V.</given-names></name><name><surname>Le</surname><given-names>T. H.</given-names></name><name><surname>Kurilshikov</surname><given-names>A.</given-names></name><name><surname>Atanasovska</surname><given-names>B.</given-names></name><name><surname>Bonder</surname><given-names>M. J.</given-names></name><name><surname>Sanna</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Individual variations in cardiovascular-disease-related protein levels are driven by genetics and gut microbiome</article-title>. <source/>Nat. Genet.
<volume>50</volume>, <fpage>1524</fpage>–<lpage>1532</lpage>.  <pub-id pub-id-type="doi">10.1038/s41588-018-0224-7</pub-id>
<pub-id pub-id-type="pmid">30250126</pub-id></mixed-citation>
</ref>
<ref id="B189">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhong</surname><given-names>C.-Y.</given-names></name><name><surname>Sun</surname><given-names>W.-W.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Wei</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Microbiota prevents cholesterol loss from the body by regulating host gene expression in mice</article-title>. <source/>Sci. Rep.
<volume>5</volume>, <fpage>10512</fpage>.  <pub-id pub-id-type="doi">10.1038/srep10512</pub-id>
<pub-id pub-id-type="pmid">26015368</pub-id></mixed-citation>
</ref>
<ref id="B190">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y.-J.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Song</surname><given-names>G.</given-names></name><name><surname>Zang</surname><given-names>S.-S.</given-names></name><name><surname>Liu</surname><given-names>Y.-X.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name></person-group> (<year>2015</year>). <article-title>Toll-like receptor-2 and -4 are associated with hyperlipidemia</article-title>. <source/>Mol. Med. Rep.
<volume>12</volume>, <fpage>8241</fpage>–<lpage>8246</lpage>.  <pub-id pub-id-type="doi">10.3892/mmr.2015.4465</pub-id>
<pub-id pub-id-type="pmid">26497845</pub-id></mixed-citation>
</ref>
<ref id="B191">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zimmermann</surname><given-names>M.</given-names></name><name><surname>Zimmermann-Kogadeeva</surname><given-names>M.</given-names></name><name><surname>Wegmann</surname><given-names>R.</given-names></name><name><surname>Goodman</surname><given-names>A. L.</given-names></name></person-group> (<year>2019</year>). <article-title>Separating host and microbiome contributions to drug pharmacokinetics and toxicity</article-title>. <source/>Science
<volume>363</volume>, <fpage>eaat9931</fpage>.  <pub-id pub-id-type="doi">10.1126/science.aat9931</pub-id>
<pub-id pub-id-type="pmid">30733391</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>